




US 20180261781A1

(19) **United States**(12) **Patent Application Publication**
LEE et al.(10) **Pub. No.: US 2018/0261781 A1**(43) **Pub. Date: Sep. 13, 2018**(54) **OGANOMETALLIC COMPOUND, ORGANIC
LIGHT-EMITTING DEVICE INCLUDING
THE ORGANOMETALLIC COMPOUND,
AND DIAGNOSTIC COMPOSITION
INCLUDING THE ORGANOMETALLIC
COMPOUND**(52) **U.S. Cl.**
CPC **H01L 51/0087** (2013.01); **H01L 51/5024**
(2013.01); **C09K 11/06** (2013.01); **C07F**
15/0086 (2013.01)(71) Applicant: **Samsung Electronics Co., Ltd.,**
Suwon-si (KR)(57) **ABSTRACT**(72) Inventors: **Kum Hee LEE**, Suwon-si (KR);
Banglin LEE, Suwon-si (KR); **Sungjun**
KIM, Seongnam-si (KR); **Hwayoung**
CHO, Hwaseong-si (KR); **Jongwon**
CHOI, Yongin-si (KR); **Whail CHOI**,
Seoul (KR); **Yoonhyun KWAK**, Seoul
(KR); **Ohyun KWON**, Seoul (KR)

An organometallic compound represented by Formula 1:

(21) Appl. No.: **15/913,153**(22) Filed: **Mar. 6, 2018**(30) **Foreign Application Priority Data**Mar. 7, 2017 (KR) 10-2017-0029058
Mar. 6, 2018 (KR) 10-2018-0026193**Publication Classification**(51) **Int. Cl.**
H01L 51/00 (2006.01)
C07F 15/00 (2006.01)
C09K 11/06 (2006.01)

Formula 1

wherein, in Formula 1, groups and variables are the same
as described in the specification.**10****19****15****11**

FIGURE

10

19
15
11

**ORGANOMETALLIC COMPOUND, ORGANIC
LIGHT-EMITTING DEVICE INCLUDING
THE ORGANOMETALLIC COMPOUND,
AND DIAGNOSTIC COMPOSITION
INCLUDING THE ORGANOMETALLIC
COMPOUND**

**CROSS-REFERENCE TO RELATED
APPLICATION**

[0001] This application claims priority to Korean Patent Application No. 10-2017-0029058, filed on Mar. 7, 2017, and Korean Patent Application No. 10-2018-0026193, filed on Mar. 6, 2018, in the Korean Intellectual Property Office, and all the benefits accruing therefrom under 35 U.S.C. 119, the content of which is incorporated herein in its entirety by reference.

BACKGROUND

1. Field

[0002] One or more embodiments relate to an organometallic compound, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound.

2. Description of the Related Art

[0003] Organic light-emitting devices (OLEDs) are self-emission devices, which have superior characteristics in terms of a viewing angle, a response time, a brightness, a driving voltage, and a response speed, and produce full-color images.

[0004] A typical organic light-emitting device includes an anode, a cathode, and an organic layer disposed between the anode and the cathode, wherein the organic layer includes an emission layer. A hole transport region may be disposed between the anode and the emission layer, and an electron transport region may be disposed between the emission layer and the cathode. Holes provided from the anode may move toward the emission layer through the hole transport region, and electrons provided from the cathode may move toward the emission layer through the electron transport region. The holes and the electrons recombine in the emission layer to produce excitons. These excitons transit from an excited state to a ground state, thereby generating light.

[0005] Meanwhile, organometallic compounds may be used to monitor, sense, or detect a variety of biological materials including cells and proteins. An example of the luminescent compounds includes a phosphorescent luminescent compound.

[0006] Various types of organic light emitting devices are known. However, there still remains a need in OLEDs having low driving voltage, high efficiency, high brightness, and long lifespan.


SUMMARY

[0007] One or more embodiments include a novel organometallic compound, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound.

[0008] Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments.

[0009] According to one or more embodiments, an organometallic compound is represented by Formula 1:

Formula 1



[0010] In Formula 1,

[0011] M may be a first-row transition metal of the Periodic Table of Elements, a second-row transition metal of the Periodic Table of Elements, or a third-row transition metal of the Periodic Table of Elements,

[0012] X₁ may be N,

[0013] X₂ to X₄ may each independently be C or N,

[0014] two bonds selected from a bond between X₁ and M, a bond between X₂ and M, a bond between X₃ and M, and a bond between X₄ and M may each be a coordinate bond, and the others thereof may each be a covalent bond,

[0015] Y₁ to Y₆ may each independently be C or N,

[0016] Y₇ and Y₈ may each independently be C, N, O, Si, or S,

[0017] X₁ and Y₇, X₁ and Y₁, X₂ and Y₂, X₂ and Y₃, X₃ and Y₄, X₃ and Y₅, X₄ and Y₆, and X₄ and Y₈ may each be linked via a chemical bond,

[0018] CY₁ may be a C₁-C₃₀ heterocyclic group,

[0019] CY₂ to CY₄ may each independently be a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group,

[0020] T₁ to T₃ may each independently be selected from $\text{---}[\text{L}_5]_{b5}\text{---}(\text{R}_5)\text{---}^*$, $\text{---}\text{B}(\text{R}_5)\text{---}^*$, $\text{---}\text{P}(\text{R}_5)\text{---}^*$, $\text{---}\text{C}(\text{R}_5)(\text{R}_6)\text{---}^*$, $\text{---}\text{Si}(\text{R}_5)(\text{R}_6)\text{---}^*$, $\text{---}\text{Ge}(\text{R}_5)(\text{R}_6)\text{---}^*$, $\text{---}\text{S}\text{---}^*$, $\text{---}\text{Se}\text{---}^*$, $\text{---}\text{O}\text{---}^*$, $\text{---}\text{C}(=\text{O})\text{---}^*$, $\text{---}\text{S}(=\text{O})\text{---}^*$, $\text{---}\text{S}(=\text{O})_2\text{---}^*$, $\text{---}\text{C}(\text{R}_5)=$, $\text{---}\text{C}(\text{R}_5)\text{---}^*$, $\text{---}\text{C}(\text{R}_5)=\text{C}(\text{R}_6)\text{---}^*$, $\text{---}\text{C}(=\text{S})\text{---}^*$, and $\text{---}\text{C}\equiv\text{C}\text{---}^*$,


[0021] L₅ may be selected from a single bond, a substituted or unsubstituted C₅-C₃₀ carbocyclic group, and a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

[0022] b₅ may be selected from 1 to 3, wherein, when b₅ is two or more, two or more groups L₅ may be identical to or different from each other,

[0023] R₅ and R₆ may optionally be linked via a first linking group to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

[0024] n₁ to n₃ may each independently be 0, 1, 2, or 3, wherein, when n₁ is zero, $\text{---}(\text{T}_1)_{n1}\text{---}^*$ may be a single bond, when n₂ is zero, $\text{---}(\text{T}_2)_{n2}\text{---}^*$ may be a single bond, and when n₃ is zero, $\text{---}(\text{T}_3)_{n3}\text{---}^*$ may be a single bond,

[0025] R_{71} in Formula 1 may be a group represented by Formula 71,



Formula 71

[0026] wherein, in Formula 71,

[0027] L_{71} may be selected from:

[0028] a C_2-C_{60} alkylene group; and

[0029] a C_2-C_{60} alkylene group substituted with at least one selected from deuterium, a deuterated C_1-C_{60} alkyl group, a C_3-C_{10} cycloalkyl group, and a C_3-C_{10} cycloalkenyl group,

[0030] b_{71} may be 0, 1, or 2,


[0031] T_{71} may be selected from:

[0032] a C_1-C_{60} alkyl group; and

[0033] a C_1-C_{60} alkyl group substituted with at least one selected from deuterium, a deuterated C_1-C_{60} alkyl group, a C_3-C_{10} cycloalkyl group, and a C_3-C_{10} cycloalkenyl group,

[0034] c_{71} may be an integer from 1 to 10,

[0035] R_{72} in Formula 1 may be a group represented by Formula 72,



Formula 72

[0036] wherein, in Formula 72,

[0037] L_{72} may be selected from:

[0038] a C_6-C_{60} arylene group, a C_1-C_{60} heteroarylene group, a divalent non-aromatic condensed polycyclic group, and a divalent non-aromatic condensed heteropolycyclic group; and

[0039] a C_6-C_{60} arylene group, a C_1-C_{60} heteroarylene group, a divalent non-aromatic condensed polycyclic group, and a divalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, a C_1-C_{60} alkyl group, a deuterated C_1-C_{60} alkyl group, a C_3-C_{10} cycloalkyl group, a C_1-C_{10} heterocycloalkyl group, a C_3-C_{10} cycloalkenyl group, a C_1-C_{10} heterocycloalkenyl group, a C_6-C_{60} aryl group, a C_1-C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group,

[0040] b_{72} may be 0, 1, or 2,

[0041] T_{72} may be selected from:

[0042] a C_6-C_{60} aryl group, a C_1-C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group; and

[0043] a C_6-C_{60} aryl group, a C_1-C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, a C_1-C_{60} alkyl group, a deuterated C_1-C_{60} alkyl group, a C_3-C_{10} cycloalkyl group, a C_1-C_{10} heterocycloalkyl group, a C_3-C_{10} cycloalkenyl group, a C_1-C_{10} heterocycloalkenyl group, a C_6-C_{60} aryl group, a C_1-C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group,

[0044] c_{72} may be an integer from 1 to 10,

[0045] wherein, in Formula 1,

[0046] a_{71} and a_{72} may each independently be an integer from 1 to 5,

[0047] R_1 to R_6 may each independently be selected from hydrogen, deuterium, $-Cl$, $-Br$, $-I$, a hydroxyl

group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C_1-C_{60} alkyl group, a substituted or unsubstituted C_2-C_{60} alkenyl group, a substituted or unsubstituted C_2-C_{60} alkynyl group, a substituted or unsubstituted C_1-C_{60} alkoxy group, a substituted or unsubstituted C_3-C_{10} cycloalkyl group, a substituted or unsubstituted C_1-C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3-C_{10} cycloalkenyl group, a substituted or unsubstituted C_1-C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6-C_{60} aryl group, a substituted or unsubstituted C_6-C_{60} aryloxy group, a substituted or unsubstituted C_6-C_{60} arylthio group, a substituted or unsubstituted C_7-C_{60} arylalkyl group, a substituted or unsubstituted C_1-C_{60} heteroaryl group, a substituted or unsubstituted C_1-C_{60} heteroaryloxy group, a substituted or unsubstituted C_1-C_{60} heteroarylthio group, a substituted or unsubstituted C_2-C_{60} heteroarylalkyl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, $-N(Q_1)(Q_2)$, $-Si(Q_3)(Q_4)(Q_5)$, $-B(Q_6)(Q_7)$, and $-P(=O)(Q_8)(Q_9)$,

[0048] a_1 to a_4 may each independently be 0, 1, 2, 3, 4, or 5,

[0049] Formula 1 does not include fluorine ($-F$),

[0050] two of groups R_1 in the number of a_1 may optionally be linked to form a substituted or unsubstituted C_5-C_{30} carbocyclic group or a substituted or unsubstituted C_1-C_{30} heterocyclic group,

[0051] two of groups R_2 in the number of a_2 may optionally be linked to form a substituted or unsubstituted C_5-C_{30} carbocyclic group or a substituted or unsubstituted C_1-C_{30} heterocyclic group,

[0052] two of groups R_3 in the number of a_3 may optionally be linked to form a substituted or unsubstituted C_5-C_{30} carbocyclic group or a substituted or unsubstituted C_1-C_{30} heterocyclic group,

[0053] two of groups R_4 in the number of a_4 may optionally be linked to form a substituted or unsubstituted C_5-C_{30} carbocyclic group or a substituted or unsubstituted C_1-C_{30} heterocyclic group,

[0054] two or more neighboring groups selected from R_1 to R_4 may optionally be linked to form a substituted or unsubstituted C_5-C_{30} carbocyclic group or a substituted or unsubstituted C_1-C_{30} heterocyclic group,

[0055] one of R_5 and R_6 and one of R_1 to R_4 may optionally be linked to form a substituted or unsubstituted C_5-C_{30} carbocyclic group or a substituted or unsubstituted C_1-C_{30} heterocyclic group,

[0056] at least one substituent of the substituted C_5-C_{30} carbocyclic group, the substituted C_1-C_{30} heterocyclic group, the substituted C_1-C_{60} alkyl group, the substituted C_2-C_{60} alkenyl group, the substituted C_2-C_{60} alkynyl group, the substituted C_1-C_{60} alkoxy group, the substituted C_3-C_{10} cycloalkyl group, the substituted C_1-C_{10} heterocycloalkyl group, the substituted C_3-C_{10} cycloalkenyl group, the substituted C_1-C_{10} heterocycloalkenyl group, the substituted C_6-C_{60} aryl group, the substituted C_6-C_{60} aryloxy group, the substituted C_6-C_{60} arylthio group, the substituted C_7-C_{60} arylalkyl

group, the substituted C_1 - C_{60} heteroaryl group, the substituted C_1 - C_{60} heteroaryloxy group, the substituted C_1 - C_{60} heteroarylthio group, the substituted C_2 - C_{60} heteroarylalkyl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be selected from:

[0057] deuterium, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{CD}_3$, $-\text{CD}_2\text{H}$, $-\text{CDH}_2$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, and a C_1 - C_{60} alkoxy group;

[0058] a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, and a C_1 - C_{60} alkoxy group, each substituted with at least one selected from deuterium, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{CD}_3$, $-\text{CD}_2\text{H}$, $-\text{CDH}_2$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_3 - C_{10} cycloalkyl group, a C_1 - C_{10} heterocycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_6 - C_{60} aryloxy group, a C_6 - C_{60} arylthio group, a C_7 - C_{60} arylalkyl group, a C_1 - C_{60} heteroaryl group, a C_1 - C_{60} heteroaryloxy group, a C_1 - C_{60} heteroarylthio group, a C_2 - C_{60} heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, $-\text{N}(\text{Q}_{11})(\text{Q}_{12})$, $-\text{Si}(\text{Q}_{13})(\text{Q}_{14})(\text{Q}_{15})$, $-\text{B}(\text{Q}_{16})(\text{Q}_{17})$, and $-\text{P}(=\text{O})(\text{Q}_{18})(\text{Q}_{19})$;

[0059] a C_3 - C_{10} cycloalkyl group, a C_1 - C_{10} heterocycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_6 - C_{60} aryloxy group, a C_6 - C_{60} arylthio group, a C_7 - C_{60} arylalkyl group, a C_1 - C_{60} heteroaryl group, a C_1 - C_{60} heteroaryloxy group, a C_1 - C_{60} heteroarylthio group, a C_2 - C_{60} heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

[0060] a C_3 - C_{10} cycloalkyl group, a C_1 - C_{10} heterocycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_6 - C_{60} aryloxy group, a C_6 - C_{60} arylthio group, a C_7 - C_{60} arylalkyl group, a C_1 - C_{60} heteroaryl group, a C_1 - C_{60} heteroaryloxy group, a C_1 - C_{60} heteroarylthio group, a C_2 - C_{60} heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, $-\text{CD}_3$, $-\text{CD}_2\text{H}$, $-\text{CDH}_2$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, a C_1 - C_{60} alkoxy group, a C_3 - C_{10} cycloalkyl group, a C_1 - C_{10} heterocycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a

C_6 - C_{60} aryloxy group, a C_6 - C_{60} arylthio group, a C_7 - C_{60} arylalkyl group, a C_1 - C_{60} heteroaryl group, a C_1 - C_{60} heteroaryloxy group, a C_1 - C_{60} heteroarylthio group, a C_2 - C_{60} heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, $-\text{N}(\text{Q}_{21})(\text{Q}_{22})$, $-\text{Si}(\text{Q}_{23})(\text{Q}_{24})(\text{Q}_{25})$, $-\text{B}(\text{Q}_{26})(\text{Q}_{27})$, and $-\text{P}(=\text{O})(\text{Q}_{28})(\text{Q}_{29})$; and

[0061] $-\text{N}(\text{Q}_{31})(\text{Q}_{32})$, $-\text{Si}(\text{Q}_{33})(\text{Q}_{34})(\text{Q}_{35})$, $-\text{B}(\text{Q}_{36})(\text{Q}_{37})$, and $-\text{P}(=\text{O})(\text{Q}_{38})(\text{Q}_{39})$, and

[0062] Q_1 to Q_9 , Q_{11} to Q_{19} , Q_{21} to Q_{29} , and Q_{31} to Q_{39} may each independently be selected from hydrogen, deuterium, $-\text{Cl}$, $-\text{Br}$, $-\text{I}$, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, a C_1 - C_{60} alkoxy group, a C_3 - C_{10} cycloalkyl group, a C_1 - C_{10} heterocycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_6 - C_{60} aryloxy group, a C_6 - C_{60} arylthio group, a C_7 - C_{60} arylalkyl group, a C_1 - C_{60} heteroaryl group, a C_1 - C_{60} heteroaryloxy group, a C_1 - C_{60} heteroarylthio group, a C_2 - C_{60} heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

[0063] According to one or more embodiments, an organic light-emitting device includes:

[0064] a first electrode;

[0065] a second electrode; and

[0066] an organic layer that is disposed between the first electrode and the second electrode,

[0067] wherein the organic layer includes an emission layer and at least one of the organometallic compound.

[0068] The organometallic compound may act as a dopant in the organic layer.

[0069] According to one or more embodiments, a diagnostic composition includes at least one of the organometallic compound represented by Formula 1.

BRIEF DESCRIPTION OF THE DRAWING

[0070] These and/or other aspects will become apparent and more readily appreciated from the following description of the embodiments, taken in conjunction with the FIGURE which is a schematic view of an organic light-emitting device according to an embodiment.

DETAILED DESCRIPTION

[0071] Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the figures, to explain aspects of the present description. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items. Expressions such as "at least one of," when preceding

a list of elements, modify the entire list of elements and do not modify the individual elements of the list.

[0072] It will be understood that when an element is referred to as being “on” another element, it can be directly in contact with the other element or intervening elements may be present therebetween. In contrast, when an element is referred to as being “directly on” another element, there are no intervening elements present.

[0073] It will be understood that, although the terms first, second, third etc. may be used herein to describe various elements, components, regions, layers, and/or sections, these elements, components, regions, layers, and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or section.

[0074] Thus, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of the present embodiments.

[0075] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0076] The term “or” means “and/or.” It will be further understood that the terms “comprises” and/or “comprising,” or “includes” and/or “including” when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof.


[0077] Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this general inventive concept belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

[0078] Exemplary embodiments are described herein with reference to cross section illustrations that are schematic illustrations of idealized embodiments. As such, variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances, are to be expected. Thus, embodiments described herein should not be construed as limited to the particular shapes of regions as illustrated herein but are to include deviations in shapes that result, for example, from manufacturing. For example, a region illustrated or described as flat may, typically, have rough and/or nonlinear features. Moreover, sharp angles that are illustrated may be rounded. Thus, the regions illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the precise shape of a region and are not intended to limit the scope of the present claims.

[0079] “About” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (i.e., the limitations of the measurement

system). For example, “about” can mean within one or more standard deviations, or within $\pm 30\%$, 20% , 10% , 5% of the stated value.

[0080] In an embodiment, an organometallic compound is provided. The organometallic compound according to an embodiment may be represented by Formula 1 below:



[0081] M in Formula 1 may be a first-row transition metal of the Periodic Table of Elements, a second-row transition metal of the Periodic Table of Elements, and a third-row transition metal of the Periodic Table of Elements.

[0082] For example, M in Formula 1 may be platinum (Pt) or palladium (Pd), but embodiments of the present disclosure are not limited thereto.

[0083] The organometallic compound represented by Formula 1 may be a neutral compound that does not consist of an ion pair of an anion and a cation.

[0084] In Formula 1, X₁ may be N, and X₂ to X₄ may each independently be C or N.

[0085] In Formula 1, two bonds selected from a bond between X₁ and M, a bond between X₂ and M, a bond between X₃ and M, and a bond between X₄ and M may each be a coordinate bond, and the others thereof may each be a covalent bond.

[0086] In an embodiment, in Formula 1, X₂ and X₃ may each be carbon, X₄ may be nitrogen, a bond between X₂ and M and a bond between X₃ and M may each be a covalent bond, and a bond between X₁ and M and a bond between X₄ and M may each be a coordinate bond, but embodiments of the present disclosure are not limited thereto.

[0087] In Formula 1, Y₁ to Y₆ may each independently be C or N, and Y₇ and Y₈ may each independently be C, N, O, Si, or S.

[0088] In an embodiment, in Formula 1, Y₁ to Y₅ may each be C, and Y₆ to Y₈ may each independently be C or N, but embodiments of the present disclosure are not limited thereto.

[0089] X₁ and Y₇, X₁ and Y₁, X₂ and Y₂, X₂ and Y₃, X₃ and Y₄, X₃ and Y₅, X₄ and Y₆, and X₄ and Y₈ in Formula 1 may each be linked via a chemical bond.

[0090] In Formula 1, CY₁ may be a C₁-C₃₀ heterocyclic group, and CY₂ to CY₄ may each independently be a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group.

[0091] For example, in Formula 1, CY₁ may be selected from a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinoxaline group, a phenanthroline group, a pyrrole group, a pyrazole

group, an imidazole group, a triazole group, a tetrazole group, an oxazole group, an isoxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline group, and CY_2 to CY_4 may each independently be selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a pyrrole group, a thiophene group, a furan group, an indole group, a benzoborol group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a benzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-on group, a dibenzothiophene 5,5-dioxide group, an azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluorene-9-on group, an azadibenzothiophene 5,5-dioxide group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrazole group, an imidazole group, a triazole group, a tetrazole group, an oxazole group, an isoxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline group.

[0092] In an embodiment, in Formula 1, CY_1 and CY_4 may each independently be selected from a pyridine group, a pyrimidine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a pyrazole group, an imidazole group, and a triazole group, and CY_2 and CY_3 may each independently be selected from a benzene group, a naphthalene group, a 1,2,3,4-tetrahydronaphthalene group, a carbazole group, a fluorene group, a dibenzothiophene group, and a benzofuran group, but embodiments of the present disclosure are not limited thereto.


[0093] “An azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluorene-9-on group, and an azadibenzothiophene 5,5-dioxide group” as used herein mean hetero-rings that respectively have the same backbones as “a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a benzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-on group, and a

dibenzothiophene 5,5-dioxide group”, provided that at least one of carbons forming rings thereof is substituted with nitrogen.


[0094] CY_1 and CY_4 in Formula 1 may be identical to each other, but embodiments of the present disclosure are not limited thereto.

[0095] In an embodiment, CY_2 and CY_3 in Formula 1 may be identical to each other, but embodiments of the present disclosure are not limited thereto.


[0096] In an embodiment, in Formula 1, a moiety represented by




and a moiety represented by



may be identical to each other, and a moiety represented by



and a moiety represented by



may be identical to each other.

[0097] In one or more embodiments, the organometallic compound may have a symmetrical structure with respect to an axis connecting M and T_1 in Formula 1.

[0098] T_1 to T_3 in Formula 1 may each independently be selected from $*-N[(L_5)_{b5}-(R_5)]-*$, $*-B(R_5)-*$, $*-P(R_5)-*$, $*-C(R_5)(R_6)-*$, $*-Si(R_5)(R_6)-*$, $*-Ge(R_5)(R_6)-*$, $*-S-*$, $*-Se-*$, $*-O-*$, $*-C(=O)-*$, $*-S(=O)-*$, $*-S(=O)_2-*$, $*-C(R_5)=*$, $*-C$

(R₅)—*, *—C(R₅)=C(R₆)—*, *—C(=S)—*, and *—C≡C—*. R₅ and R₆ are each independently the same as described below.

[0099] L₅ may be selected from a single bond, a substituted or unsubstituted C₅-C₃₀ carbocyclic group, and a substituted or unsubstituted C₁-C₃₀ heterocyclic group, and b₅ may be selected from 1 to 3 (for example, b₅ may be 1), wherein, when b₅ is two or more, two or more groups L₅ may be identical to or different from each other.

[0100] In an embodiment, L₅ may be selected from:

[0101] a single bond, a phenylene group, a naphthylene group, a fluorenylene group, a pyridinylene group, a pyrimidinylene group, and a carbazolylene group; and

[0102] a phenylene group, a naphthylene group, a fluorenylene group, a pyridinylene group, a pyrimidinylene group, and a carbazolylene group, each substituted with at least one selected from deuterium, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a phenyl group, a naphthyl group, a biphenyl group, and a terphenyl group,

[0103] but embodiments of the present disclosure are not limited thereto.

[0104] R₅ and R₆ may optionally be linked via a first linking group to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group (a C₅-C₆ 5-membered to 7-membered cyclic group; or a C₅-C₆ 5-membered to 7-membered cyclic group substituted with at least one selected from deuterium, a cyano group, a C₁-C₁₀ alkyl group, and a C₆-C₁₄ aryl group).

[0105] In an embodiment, T₁ to T₃ in Formula 1 may each independently be selected from *—N[(L₅)_{b5}-(R₅)]—*, *—B(R₅)—*, *—C(R₅)(R₆)—*, *—Si(R₅)(R₆)—*, *—S—*, *—O—*, and *—C(=O)—*, but embodiments of the present disclosure are not limited thereto.

[0106] In one or more embodiments, T₁ to T₃ in Formula 1 may each independently be selected from *—C(R₅)(R₆)—*, *—Si(R₅)(R₆)—*, and *—Ge(R₅)(R₆)—*,

[0107] R₅ and R₆ may be linked via a first linking group,

[0108] the first linking group may be selected from a single bond, *—N[(L₉)_{b9}-(R₉)]—*, *—B(R₉)—*, *—P(R₉)—*, *—C(R₉)(R₁₀)—*, *—Si(R₉)(R₁₀)—*, *—Ge(R₉)(R₁₀)—*, *—S—*, *—Se—*, *—O—*, *—C(=O)—*, *—S(=O)—*, *—S(=O)₂—*, *—C(R₉)=C(R₁₀)—*, *—C(=S)—*, and *—C≡C—*,

[0109] L₉ and b₉ are each independently the same as described in connection with L₅ and b₅,

[0110] R₉ and R₁₀ are each independently the same as described in connection with R₅, and

[0111] and * each indicate a binding site to a neighboring atom, but embodiments of the present disclosure are not limited thereto.

[0112] n₁ to n₃ in Formula 1 may each independently be 0, 1, 2, or 3, wherein, when n₁ is zero, *(T₁)_{n1}—* may be a single bond, when n₂ is zero, *(T₂)_{n2}—* may be a single bond, and when n₃ is zero, *(T₃)_{n3}—* may be a single bond. When n₁ is two or more, two or more groups T₁ may be identical to or different from each other, when n₂ is two or


more, two or more groups T₂ may be identical to or different from each other, and when n₃ is two or more, two or more groups T₃ may be identical to or different from each other.

[0113] In an embodiment, n₁ to n₃ in Formula 1 may each independently be 0 or 1.

[0114] In one or more embodiments, the sum of n₁, n₂, and n₃ in Formula 1 may be 0 or 1.

[0115] In one or more embodiments, in Formula 1, n₁ may be 1, and n₂ and n₃ may be 0 or 1.

[0116] R₇₁ in Formula 1 may be a group represented by Formula 71:



Formula 71

[0117] In Formula 71,

[0118] L₇₁ may be selected from:

[0119] a C₂-C₆₀ alkylene group; and

[0120] a C₂-C₆₀ alkylene group substituted with at least one selected from deuterium, a deuterated C₁-C₆₀ alkyl group, a C₃-C₁₀ cycloalkyl group, and a C₃-C₁₀ cycloalkenyl group,

[0121] b₇₁ may be 0, 1, or 2,

[0122] T₇₁ may be selected from:

[0123] a C₁-C₆₀ alkyl group; and

[0124] a C₁-C₆₀ alkyl group substituted with at least one selected from deuterium, a deuterated C₁-C₆₀ alkyl group, a C₃-C₁₀ cycloalkyl group, and a C₃-C₁₀ cycloalkenyl group, and

[0125] c₇₁ may be an integer from 1 to 10.

[0126] For example, in Formula 71,

[0127] L₇₁ may be selected from:

[0128] a C₂-C₁₀ alkylene group; and

[0129] a C₂-C₁₀ alkylene group substituted with at least one selected from deuterium, a deuterated C₁-C₂₀ alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbonanyl group, a norbonenyl group, a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group,

[0130] b₇₁ may be 0 or 1,


[0131] T₇₁ may be selected from:

[0132] a C₁-C₁₀ alkyl group; and

[0133] a C₁-C₁ alkyl group substituted with at least one selected from deuterium, a deuterated C₁-C₂₀ alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbonanyl group, a norbonenyl group, a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group, and

[0134] c₇₁ may be 1 or 2, but embodiments of the present disclosure are not limited thereto.

[0135] R₇₂ in Formula 1 may be a group represented by Formula 72:



Formula 72

[0136] In Formula 72,

[0137] L₇₂ may be selected from:

[0138] a C₆-C₆₀ arylene group, a C₁-C₆₀ heteroarylene group, a divalent non-aromatic condensed polycyclic group, and a divalent non-aromatic condensed heteropolycyclic group; and

[0139] a C₆-C₆₀ arylene group, a C₁-C₆₀ heteroarylene group, a divalent non-aromatic condensed polycyclic group, and a divalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, a C₁-C₆₀ alkyl group, a deu-

[0142] a C₆-C₆₀ aryl group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group; and

[0143] a C₆-C₆₀ aryl group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, a C₁-C₆₀ alkyl group, a deuterated C₁-C₆₀ alkyl group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, and

[0147] a phenylene group, a naphthylene group, a pyridinylene group, a pyrimidinylene group, a triazinylene group, a quinolinylene group, an isoquinolinylene group, a quinoxalinylene group, a quinazolinylene group, a fluorenylene group, a carbazolylenegroup, a dibenzofuranylene group, and a dibenzothio-phenylene group; and

[0148] a phenylene group, a naphthylene group, a pyridinylene group, a pyrimidinylene group, a triazinylene group, a quinolinylene group, an isoquinolinylene group, a quinoxalinylene group, a quinazolinylene group, a fluorenylene group, a carbazolyene group, a dibenzofuranylene group, and a dibenzothio-phenylene group, each substituted with at least one selected from deuterium, a C₁-C₂₀ alkyl group, a deuterated C₁-C₂₀ alkyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinalyl group, a quinazolinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, and a dibenzothiophenyl group.

[0151] a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuran group, and a dibenzothiophenyl group; and

[0152] a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a fluorenyl group, a carbazoyl group, a dibenzofuranyl group, and a dibenzothiophenyl group, each substituted with at least one selected from deuterium, a C₁-C₂₀ alkyl group, a deu-

terated C₁-C₂₀ alkyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinalyl group, a quinazolinyl group, a fluorenyl group, a carbazolyl group, a dibenzofuranyl group, and a dibenzothiophenyl group, and

[0153] c72 may be 1 or 2, but embodiments of the present disclosure are not limited thereto.

[0154] a71 and a72 in Formula 1 respectively indicate the number of groups R₇₁ and the number of groups R₇₂, and may each independently be an integer from 1 to 5. That is, CY₁ in Formula 1 is essentially substituted with at least one R₇₁ and at least one R₇₂. a71 and a72 may each independently be 1 or 2. For example, a71 and a72 may each be 1, but embodiments of the present disclosure are not limited thereto.

[10155] R₁ to R₆ in Formula 1 may each independently be selected from hydrogen, deuterium, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C₁–C₆₀ alkyl group, a substituted or unsubstituted C₂–C₆₀ alkenyl group, a substituted or unsubstituted C₂–C₆₀ alkynyl group, a substituted or unsubstituted C₁–C₆₀ alkoxy group, a substituted or unsubstituted C₃–C₁₀ cycloalkyl group, a substituted or unsubstituted C₁–C₁₀ heterocycloalkyl group, a substituted or unsubstituted C₃–C₁₀ cycloalkenyl group, a substituted or unsubstituted C₁–C₁₀ heterocycloalkenyl group, a substituted or unsubstituted C₆–C₆₀ aryl group, a substituted or unsubstituted C₆–C₆₀ aryloxy group, a substituted or unsubstituted C₆–C₆₀ arylthio group, a substituted or unsubstituted C₇–C₆₀ arylalkyl group, a substituted or unsubstituted C₁–C₆₀ heteroaryl group, a substituted or unsubstituted C₁–C₆₀ heteroaryloxy group, a substituted or unsubstituted C₁–C₆₀ heteroarylthio group, a substituted or unsubstituted C₂–C₆₀ heteroarylalkyl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(=O)(Q₈)(Q₉). Q₁ to Q₉ are each independently the same as described herein.

[0156] For example, R_1 to R_6 may each independently be selected from:

[0157] hydrogen, deuterium, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, C₁-C₂₀ alkyl group, and a C₁-C₂₀ alkoxy group;

[0158] a C₁-C₂₀ alkyl group and a C₁-C₂₀ alkoxy group, each substituted with at least one selected from deuterium, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀ alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl

group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

[0159] a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group;

[0160] a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group, each substituted with at least one selected from deuterium, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl

group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, —N(Q₃₁)(Q₃₂), and —Si(Q₃₃)(Q₃₄)(Q₃₅); and

[0161] —N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(=O)(Q₈)(Q₉), and

[0162] Q₁ to Q₉ and Q₃₁ to Q₃₅ may each independently be selected from:

[0163] —CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃, —CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCH₃, —CHDCD₂H, —CHDCDH₂, —CHDCH₂, —CD₂CD₃, —CD₂CD₂H, and —CD₂CDH₂;

[0164] an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

[0165] an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C₁-C₁₀ alkyl group, and a phenyl group.

[0166] In one or more embodiments, in Formula 1,

[0167] R₁ to R₆ may each independently be selected from hydrogen, deuterium, a cyano group, a nitro group, —CH₃, —CD₃, —CD₂H, —CDH₂, —OCH₃, groups represented by Formulae 9-1 to 9-19, groups represented by Formulae 10-1 to 10-168, —N(Q₁)(Q₂), and —Si(Q₃)(Q₄)(Q₅),














[0168] R₇₁ may be selected from —CH₃, —CD₃, —CD₂H, —CDH₂, groups represented by Formulae 9-1 to 9-19, and groups represented by Formulae 10-5 to 10-8, 10-11, and 10-12, and

[0169] R₇₂ may be selected from groups represented by Formulae 10-13 to 10-152 and 10-159 to 10-168, but embodiments of the present disclosure are not limited thereto:



Formula 9-1

-continued



Formula 9-2

Formula 9-3

Formula 9-4

Formula 9-5

Formula 9-6

Formula 9-7

Formula 9-8

Formula 9-9

Formula 9-10

Formula 9-11

Formula 9-12

Formula 9-13













Formula 9-14

Formula 9-15

Formula 9-16

Formula 9-17

-continued



Formula 9-18

Formula 9-19

Formula 10-1

Formula 10-2

Formula 10-3

Formula 10-4

Formula 10-5

Formula 10-6











Formula 10-7

Formula 10-8


Formula 10-9

Formula 10-10


-continued




Formula 10-11




Formula 10-12




Formula 10-13




Formula 10-14




Formula 10-15




Formula 10-16




Formula 10-17




Formula 10-18



Formula 10-19



Formula 10-20



-continued

Formula 10-21

Formula 10-22

Formula 10-23

Formula 10-24

Formula 10-25

Formula 10-26











Formula 10-27

Formula 10-28

Formula 10-29

Formula 10-30

-continued



Formula 10-31

Formula 10-32

Formula 10-33

Formula 10-34

Formula 10-35

Formula 10-36











Formula 10-37

Formula 10-38

Formula 10-39

Formula 10-40

-continued



Formula 10-41

Formula 10-42

Formula 10-43

Formula 10-44

Formula 10-45

Formula 10-46









Formula 10-47

Formula 10-48

Formula 10-49

Formula 10-50

-continued



Formula 10-51

Formula 10-52

Formula 10-53

Formula 10-54









Formula 10-55

Formula 10-56

Formula 10-57

Formula 10-58

-continued



Formula 10-59

Formula 10-60

Formula 10-61

Formula 10-62










Formula 10-63

Formula 10-64

Formula 10-65

Formula 10-66

-continued




-continued


Formula 10-67




Formula 10-68



Formula 10-69




Formula 10-70




Formula 10-71

Formula 10-72



Formula 10-73

Formula 10-74



Formula 10-75

Formula 10-76












Formula 10-77

Formula 10-78

Formula 10-79

Formula 10-80

-continued



Formula 10-81

Formula 10-82

Formula 10-83

Formula 10-84

Formula 10-85

Formula 10-86

Formula 10-87












Formula 10-88

Formula 10-89

Formula 10-90

Formula 10-91

-continued



Formula 10-92

Formula 10-93

Formula 10-94

Formula 10-95

Formula 10-96

Formula 10-97

Formula 10-98










Formula 10-99

Formula 10-100

Formula 10-101


Formula 10-102

-continued




-continued

Formula 10-103




Formula 10-104

Formula 10-105




Formula 10-106


Formula 10-107




Formula 10-108




Formula 10-109



Formula 10-110



Formula 10-111



Formula 10-112

Formula 10-113

Formula 10-114








Formula 10-115

Formula 10-116

Formula 10-117

Formula 10-118

-continued



Formula 10-119

Formula 10-120

Formula 10-121








Formula 10-122

Formula 10-123

Formula 10-124

Formula 10-125

-continued



Formula 10-126

Formula 10-127

Formula 10-128








Formula 10-129

Formula 10-130

Formula 10-131

Formula 10-132

-continued



Formula 10-133

Formula 10-134

Formula 10-135









Formula 10-136

Formula 10-137

Formula 10-138

Formula 10-139

-continued



Formula 10-140

Formula 10-141

Formula 10-142

Formula 10-143













Formula 10-144

Formula 10-145

Formula 10-146

Formula 10-147

-continued



Formula 10-148

Formula 10-149

Formula 10-150

Formula 10-151

Formula 10-152

Formula 10-153

Formula 10-154

Formula 10-155








Formula 10-156

Formula 10-157

Formula 10-158

Formula 10-159

-continued



Formula 10-160

Formula 10-161

Formula 10-162


Formula 10-163

Formula 10-164


Formula 10-165

Formula 10-166

-continued



Formula 10-167



Formula 10-168

[0170] In Formulae 9-1 to 9-19 and 10-1 to 10-168, * indicates a binding site to a neighboring atom, “Ph” indicates a phenyl group, “Cz” indicates a carbazolyl group, and “TMS” indicates a trimethylsilyl group.

[0171] a1, a2, a3, and a4 in Formula 1 respectively indicate the number of groups R_1 , the number of groups R_2 , the number of groups R_3 , and the number of groups R_4 , and may each independently be 0, 1, 2, 3, 4, or 5. When a1 is two or more, two or more groups R_1 may be identical to or different from each other, when a2 is two or more, two or more groups R_2 may be identical to or different from each other, when a3 is two or more, two or more groups R_3 may be identical to or different from each other, and when a4 is two or more, two or more groups R_4 may be identical to or different from each other, but embodiments of the present disclosure are not limited thereto.

[0172] In Formula 1, two of groups R_1 in the number of a1 may optionally be linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group, two of groups R_2 in the number of a2 may optionally be linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group, when two of groups R_3 in the number of a3 may optionally be linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group, two of groups R_4 in the number of a4 may optionally be linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group, two or more neighboring groups selected from R_1 to R_4 may optionally be linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group, and one of R_5 and R_6 and one of R_1 to R_4 may optionally be linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group.

[0173] For example, i) a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group, formed by linking two of groups R_1 in the number of a1, ii) a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group, formed by two of groups R_2 in the number of a2, iii) a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30}

heterocyclic group, formed by linking two of groups R_3 in the number of a3, iv) a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group, formed by linking two of groups R_4 in the number of a4, v) a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group, formed by linking two neighboring groups selected from R_1 to R_4 , and vi) a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group, formed by linking one of R_5 and R_6 and one of R_1 to R_4 in Formula 1 may each independently be selected from:

[0174] a pentadiene group, a cyclohexane group, a cyclopentane group, an adamantane group, a bicycloheptane group, a bicyclo-octane group, a benzene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a benzofuran group, an indene group, an indole group, a benzosilole group, an azabenzothiophene group, an azabenzofuran group, an azaindene group, an azaindole group, and an azabenzosilole group; and


[0175] a pentadiene group, a cyclohexane group, a cycloheptane group, an adamantane group, a bicycloheptane group, a bicyclo-octane group, a benzene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a benzofuran group, an indene group, an indole group, a benzosilole group, an azabenzothiophene group, an azabenzofuran group, an azaindene group, an azaindole group, and an azabenzosilole group, each substituted with at least one R_{10} .

[0176] but embodiments of the present disclosure are not limited thereto.

[0177] R_{10} is the same as described in connection with R_1 .


[0178] The organometallic compound represented by Formula 1 does not include fluorine (F).

[0179] In an embodiment, a moiety represented by




in Formula 1 may be selected from groups represented by Formulae CY1-1 to CY1-6:

Formula CY1-1




-continued




Formula CY1-2


in Formula 1 may be selected from groups represented by Formulae CY2-1 to CY2-25:




Formula CY1-3




Formula CY2-1




Formula CY1-4




Formula CY2-2




Formula CY1-5




Formula CY2-3



Formula CY1-6



Formula CY2-4



Formula CY2-5


[0180] In Formulae CY1-1 to CY1-6,

[0181] X_1 , R_{71} , R_{72} , and R_1 are each independently the same as described herein,


[0182] c_2 may be an integer from 0 to 2, and

[0183] and $*$ ' each indicate a binding site to a neighboring atom.


[0184] In one or more embodiments, a moiety represented by



Formula CY2-6




Formula CY2-7




-continued


Formula CY2-14




Formula CY2-15




Formula CY2-16




Formula CY2-17




Formula CY2-18




Formula CY2-19



Formula CY2-20




Formula CY2-21




-continued


Formula CY2-22




Formula CY2-23



Formula CY2-24




Formula CY2-25




in Formula 1 may be selected from groups represented by Formulae CY3-1 to CY3-25:


Formula CY3-1




Formula CY3-2




Formula CY3-3




Formula CY3-4




Formula CY3-5



Formula CY3-6



Formula CY3-7



[0185] In Formulae CY2-1 to CY2-25,

[0186] X_2 and R_2 are each independently the same as described herein,

[0187] X_{21} may be O, S, $N(R_{21})$, or $C(R_{21})(R_{22})$,

[0188] R_{21} to R_{28} are each independently the same as described in connection with R_2 ,

[0189] c_5 may be an integer from 0 to 5,


[0190] c_4 may be an integer from 0 to 4,

[0191] c_3 may be an integer from 0 to 3,







[0192] c_2 may be an integer from 0 to 2, and

[0193] *, *, and *'' each indicate a binding site to a neighboring atom.

[0194] In one or more embodiments, a moiety represented by



-continued



Formula CY3-8

Formula CY3-9








Formula CY3-10

Formula CY3-11

Formula CY3-12

Formula CY3-13

-continued



Formula CY3-14

화학식 CY3-15

Formula CY3-16

Formula CY3-17


Formula CY3-18

Formula CY3-19


Formula CY3-20

-continued


Formula CY3-21




Formula CY3-22




Formula CY3-23



Formula CY3-24



Formula CY3-25



[0195] In Formulae CY3-1 to CY3-25,

[0196] X_3 and R_3 are each independently the same as described herein,[0197] X_{31} may be O, S, $N(R_{31})$, or $C(R_{31})(R_{32})$,[0198] R_{31} to R_{38} are each independently the same as described in connection with R_3 ,

[0199] c5 may be an integer from 0 to 5,


[0200] c4 may be an integer from 0 to 4,

[0201] c3 may be an integer from 0 to 3,

[0202] c2 may be an integer from 0 to 2, and


[0203] *, *', and *'' each indicate a binding site to a neighboring atom.

[0204] In one or more embodiments, a moiety represented by




in Formula 1 may be selected from groups represented by Formulae CY4-1 to CY4-35:


Formula CY4-1




Formula CY4-2




Formula CY4-3




Formula CY4-4




Formula CY4-5




-continued




Formula CY4-6




Formula CY4-7




Formula CY4-8




Formula CY4-9



Formula CY4-10




Formula CY4-11




Formula CY4-12


-continued




Formula CY4-13




Formula CY4-14




Formula CY4-15



Formula CY4-16




Formula CY4-17




Formula CY4-18

-continued


Formula CY4-26




Formula CY4-27




Formula CY4-28





Formula CY4-29




Formula CY4-30




Formula CY4-31




-continued




Formula CY4-32



Formula CY4-33



Formula CY4-34



Formula CY4-35


[0205] In Formulae CY4-1 to CY4-35,

[0206] X_4 and R_4 are each independently the same as described herein,[0207] X_{41} may be O, S, $N(R_{41})$, or $C(R_{41})(R_{42})$,[0208] R_{71a} is the same as described in connection with R_{71} ,[0209] R_{72a} is the same as described in connection with R_{72} ,[0210] R_{41} to R_{48} are each independently the same as described in connection with R_4 ,[0211] c_6 may be an integer from 0 to 6,[0212] c_5 may be an integer from 0 to 5,[0213] c_4 may be an integer from 0 to 4,[0214] c_3 may be an integer from 0 to 3,[0215] c_2 may be an integer from 0 to 2, and

[0216] * and *' each indicate a binding site to a neighboring atom.


[0217] In one or more embodiments,

[0218] a moiety represented by




in Formula 1 may be selected from groups represented by Formulae CY1(1) and CY1(2), and/or

[0219] a moiety represented by




in Formula 1 may be selected from groups represented by Formulae CY2(1) to CY2(4), and/or

[0220] a moiety represented by




in Formula 1 may be selected from groups represented by Formulae CY3(1) to CY3(4), and/or

[0221] a moiety represented by










in Formula 1 may be selected from groups represented by Formulae CY4(1) to CY4(19), but embodiments of the present disclosure are not limited thereto:

Formula CY1(1)



-continued



Formula CY1(2)

Formula CY2(1)

Formula CY2(2)









Formula CY2(3)

Formula CY2(4)

Formula CY3(1)

Formula CY3(2)

-continued



Formula CY3(3)

Formula CY3(4)

Formula CY4(1)

Formula CY4(2)


Formula CY4(3)

Formula CY4(4)


Formula CY4(5)

Formula CY4(6)


-continued




Formula CY4(7)




Formula CY4(8)




Formula CY4(9)




Formula CY4(10)



Formula CY4(11)




Formula CY4(12)




Formula CY4(13)


-continued




Formula CY4(14)




Formula CY4(15)




Formula CY4(16)



Formula CY4(17)



Formula CY4(18)



Formula CY4(19)

[0222] In Formulae CY1(1), CY1(2), CY2(1) to CY2(4), CY3(1) to CY3(4), and CY4(1) to CY4(19),

[0223] X_1 , R_1 , R_{71} , R_{72} , X_2 , R_2 , X_3 , R_3 , X_4 , and R_4 are each independently the same as described herein,

[0224] X_{41} may be O, S, N(R_{41}), or C(R_{41})(R_{42}),

[0225] R_{4a} , R_{4b} , R_{41} , and R_{42} are each independently the same as described in connection with R_4 ,


[0226] R_{71a} is the same as described in connection with R_{71} ,

[0227] R_{72a} is the same as described in connection with R_{72} , and

[0228] *, *', and *'' each indicate a binding site to a neighboring atom.

[0229] In one or more embodiments, the organometallic compound may be represented by Formula 1(1):

Formula 1(1)



[0230] In Formula 1(1),

[0231] M , X_1 to X_4 , Y_1 to Y_8 , CY_1 to CY_4 , T_2 , T_3 , $b2$, $b3$, R_{71} , R_{72} , $a71$, $a72$, R_1 to R_4 , and $a1$ to $a4$ are each independently the same as described herein,

[0232] CY_5 and CY_6 may each independently be a C_5 - C_{30} carbocyclic group or a C_1 - C_{30} heterocyclic group,

[0233] R_{51} and R_{61} are each independently the same as described in connection with R_1 ,

[0234] $a51$ and $a61$ may each independently be 0, 1, 2, or 3,

[0235] T_4 may be C, Si, or Ge,

[0236] T_5 may be selected from a single bond, *—N[(L_7) b_7 —(R_7)]—*', *—C(R_7)(R_8)—*', *—Si(R_7)(R_8)—*', *—Ge(R_7)(R_8)—*', *—S—*', *—Se—*', *—O—*', *—C(=O)—*', *—S(=O)—*', *—S(=O)₂—*', *—C(R_7)=C(R_8)—*', *—C(=S)—*', and *—C≡C—*,'




[0237] L_7 and b_7 are each independently the same as described in connection with L_5 and b_5 ,

[0238] R_7 and R_8 are each independently the same as described in connection with R_5 , and


[0239] * and *' each indicate a binding site to a neighboring atom.

[0240] For example, T_5 may be selected from a single bond, *—N[(L_7) b_7 —(R_7)]—*', *—C(R_7)(R_8)—*', *—Si(R_7)(R_8)—*', *—Ge(R_7)(R_8)—*', *—S—*', *—O—*', and *—C(=O)—*.

[0241] The organometallic compound represented by Formula 1 may be selected from Compounds 1 to 201, but embodiments of the present disclosure are not limited thereto:




-continued




4


-continued




7




5



8




6




9

-continued




10


-continued




13




11



14




12




15

-continued


16



17




18




-continued


19



20




21




-continued


22



23




24




-continued


25




26



27




-continued




28


-continued




31




29



32




30




33

-continued




34


-continued




37




35



38




36




39

-continued




40


-continued




43




41



44




42




45

-continued




46


-continued




49




47



50




48




51

-continued




52

-continued




55


53




54



56




57




-continued

58




-continued


61




59




62




60



63




-continued




64

-continued




67


65




68




66



69




-continued




70


-continued




73




71



74




72



75


-continued

76




-continued


79




77




80




78



81




-continued




82


-continued




85




83



86




84



87


-continued

88




-continued


91




89




92



90




93




-continued

94




-continued


97




95




98




96








99



-continued




-continued




-continued

106




-continued


108



107




109




-continued

110




-continued


112



111




113




-continued

114




-continued


116



115




117




-continued

118




-continued


120




119




121




-continued




-continued




123




125




-continued




-continued




127




129




-continued




-continued



131




133




-continued

134




-continued


136



135




137




-continued

138




-continued


140



139




141




-continued

142




-continued


144




143




145




-continued




-continued



147




149




-continued

150




-continued


152



151




153




-continued


154



155




156




-continued

157




158




-continued


159



160




161




-continued

162




163




-continued

164




-continued


166






165






167



-continued




-continued




-continued


174



175




176




-continued

177




178




-continued

179




-continued


181




180



182




-continued




183

-continued




185

184




186




-continued

187





-continued

189




190

188




-continued




191


-continued




194




192



195




193




196

-continued


197



198




199




-continued

200



201




[0242] The organometallic compound represented by Formula 1 does not include fluorine. Accordingly, the organometallic compound represented by Formula 1 has relatively excellent metal-to-ligand charge-transfer (MLCT) and thus may have a short decay rate.

[0243] Also, since a_{71} and a_{72} in Formula 1 are not zero, CY_1 in Formula 1 is substituted with R_{71} and R_{72} “at the same time” as described herein. Accordingly, an electronic device, for example, an organic light-emitting device, which includes the organometallic compound represented by Formula 1, may achieve improvement in efficiency and lifespan “at the same time”.

[0244] For example, a highest occupied molecular orbital (HOMO) energy level, a lowest unoccupied molecular orbital (LUMO) energy level, a singlet (S_1) energy level, and a triplet (T_1) energy level of some of Compounds and Compound A were evaluated by using a density functional theory (DFT) method of a Gaussian program (B3LYP, structurally optimized at a level of 6-31G(d,p)). Evaluation results thereof are shown in Table 1.

TABLE 1

Compound No.	HOMO (eV)	LUMO (eV)	S ₁ energy level (eV)	T ₁ energy level (eV)
1	-4.321	-1.591	2.165	1.951
2	-4.349	-1.675	2.121	1.915
4	-4.275	-1.566	2.144	1.932
5	-4.352	-1.618	2.176	1.956
7	-4.317	-1.672	2.122	1.924
9	-4.395	-1.674	2.153	1.939
17	-4.416	-1.687	2.175	1.956
18	-4.408	-1.682	2.726	1.951
21	-4.333	-1.603	2.156	1.931
26	-4.392	-1.731	2.119	1.921
55	-4.348	-1.734	2.093	1.899
59	-4.320	-1.657	2.131	1.933
78	-4.395	-1.725	2.128	1.938
79	-4.431	-1.671	2.191	1.976
87	-4.493	-1.744	2.177	1.960
92	-4.360	-1.699	2.100	1.885
101	-4.525	-1.826	2.140	1.914
102	-4.368	-1.708	2.099	1.886
103	-4.326	-1.671	2.095	1.886
104	-4.406	-1.788	2.095	1.906
127	-4.448	-1.683	2.194	1.977
128	-4.478	-1.768	2.151	1.941
148	-4.465	-1.677	2.206	1.982
155	-4.310	-1.672	2.113	1.916
A	-4.419	-1.589	2.236	1.985



[0245] From Table 1, it can be determined that the organometallic compound represented by Formula 1 may be suitable for use in an electron device, for example, for use as a dopant for an organic light-emitting device.

[0246] Synthesis methods of the organometallic compound represented by Formula 1 may be recognizable by one of ordinary skill in the art by referring to Synthesis Examples provided below.

[0247] The organometallic compound represented by Formula 1 is suitable for use in an organic layer of an organic light-emitting device, for example, for use as a dopant in an emission layer of the organic layer. Thus, another aspect provides an organic light-emitting device that includes:

[0248] a first electrode;

[0249] a second electrode; and

[0250] an organic layer that is disposed between the first electrode and the second electrode,

[0251] wherein the organic layer includes an emission layer and at least one of the organometallic compound represented by Formula 1.

[0252] The organic light-emitting device may have, due to the inclusion of an organic layer including the organometallic compound represented by Formula 1, a low driving voltage, high efficiency, high power, high quantum efficiency, a long lifespan, a low roll-off ratio, and excellent color purity.

[0253] The organometallic compound represented by Formula 1 may be used between a pair of electrodes of an organic light-emitting device. For example, the organometallic compound represented by Formula 1 may be included in the emission layer. In this regard, the organometallic compound may act as a dopant, and the emission layer may further include a host (that is, an amount of the organometallic compound represented by Formula 1 is smaller than an amount of the host).

[0254] The expression “(an organic layer) includes at least one of organometallic compounds” as used herein may include an embodiment in which “(an organic layer) includes identical organometallic compounds represented by Formula 1” and an embodiment in which “(an organic layer) includes two or more different organometallic compounds represented by Formula 1.”

[0255] For example, the organic layer may include, as the organometallic compound, only Compound 1. In this embodiment, Compound 1 may be included in an emission layer of the organic light-emitting device. In one or more embodiments, the organic layer may include, as the organometallic compound, Compound 1 and Compound 2. In this embodiment, Compound 1 and Compound 2 may be included in an identical layer (for example, Compound 1 and Compound 2 may both be included in an emission layer).

[0256] The first electrode may be an anode, which is a hole injection electrode, and the second electrode may be a cathode, which is an electron injection electrode; or the first electrode may be a cathode, which is an electron injection electrode, and the second electrode may be an anode, which is a hole injection electrode.

[0257] In an embodiment, in the organic light-emitting device, the first electrode is an anode, and the second electrode is a cathode, and the organic layer further includes a hole transport region disposed between the first electrode and the emission layer and an electron transport region disposed between the emission layer and the second electrode, wherein the hole transport region includes a hole injection layer, a hole transport layer, an electron blocking layer, or any combination thereof, and wherein the electron transport region includes a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

[0258] The term “organic layer” as used herein refers to a single layer and/or a plurality of layers disposed between the first electrode and the second electrode of the organic light-emitting device. The “organic layer” may include, in addition to an organic compound, an organometallic complex including metal.

[0259] The FIG. 1 is a schematic view of an organic light-emitting device 10 according to an embodiment. Hereinafter, the structure of an organic light-emitting device according to an embodiment and a method of manufacturing an organic light-emitting device according to an embodiment will be described in connection with the FIGURE. The

organic light-emitting device **10** includes a first electrode **11**, an organic layer **15**, and a second electrode **19**, which are sequentially stacked.

[0260] A substrate may be additionally disposed under the first electrode **11** or above the second electrode **19**. For use as the substrate, any substrate that is used in general organic light-emitting devices may be used, and the substrate may be a glass substrate or a transparent plastic substrate, each having excellent mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and water resistance.

[0261] The first electrode **11** may be formed by depositing or sputtering a material for forming the first electrode **11** on the substrate. The first electrode **11** may be an anode. The material for forming the first electrode **11** may be selected from materials with a high work function to facilitate hole injection. The first electrode **11** may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. The material for forming the first electrode may be, for example, indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO₂), and zinc oxide (ZnO). In one or more embodiments, magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag) may be used as the material for forming the first electrode.

[0262] The first electrode **11** may have a single-layered structure or a multi-layered structure including two or more layers. For example, the first electrode **11** may have a three-layered structure of ITO/Ag/ITO, but the structure of the first electrode **110** is not limited thereto.

[0263] The organic layer **15** is disposed on the first electrode **11**.

[0264] The organic layer **15** may include a hole transport region, an emission layer, and an electron transport region.

[0265] The hole transport region may be disposed between the first electrode **11** and the emission layer.

[0266] The hole transport region may include a hole injection layer, a hole transport layer, an electron blocking layer, a buffer layer, or any combination thereof.

[0267] The hole transport region may include only either a hole injection layer or a hole transport layer. In one or more embodiments, the hole transport region may have a hole injection layer/hole transport layer structure or a hole injection layer/hole transport layer/electron blocking layer structure, which are sequentially stacked in this stated order from the first electrode **11**.

[0268] A hole injection layer may be formed on the first electrode **11** by using one or more suitable methods selected from vacuum deposition, spin coating, casting, or Langmuir-Blodgett (LB) deposition.


[0269] When a hole injection layer is formed by vacuum deposition, the deposition conditions may vary according to a compound that is used to form the hole injection layer, and the structure and thermal characteristics of the hole injection layer. For example, the deposition conditions may include a deposition temperature of about 100° C. to about 500° C., a vacuum pressure of about 10⁻⁸ torr to about 10⁻³ torr, and a deposition rate of about 0.01 Angstroms per second (Å/sec) to about 100 Å/sec, but embodiments of the present disclosure are not limited thereto.

[0270] When the hole injection layer is formed using spin coating, coating conditions may vary according to the material used to form the hole injection layer, and the structure and thermal properties of the hole injection layer. For


example, a coating speed may be from about 2,000 revolutions per minute (rpm) to about 5,000 rpm, and a temperature at which a heat treatment is performed to remove a solvent after coating may be from about 80° C. to about 200° C. However, the coating conditions are not limited thereto.

[0271] Conditions for forming a hole transport layer and an electron blocking layer may be understood by referring to conditions for forming the hole injection layer.


[0272] The hole transport region may include at least one selected from m-MTDATA, TDATA, 2-TNATA, NPB, β-NPB, TPD, Spiro-TPD, Spiro-NPB, methylated-NPB, TAPC, HMTPD, 4,4',4"-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzene sulfonic acid (PANI/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrene sulfonate) (PEDOT/PSS), polyaniline/camphor sulfonic acid (PANI/CSA), polyaniline/poly(4-styrene sulfonate) (PANI/PSS), a compound represented by Formula 201 below, and a compound represented by Formula 202 below:




-continued




2-TNATA



NPB




β-NPB




TPD


-continued




Spiro-TPD




Spiro-NPB



methylated NPB




TAPC




HMTDP

-continued

Formula 201



Formula 202



[0273] Ar_{101} and Ar_{102} in Formula 201 may each independently be selected from:

[0274] a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, and a pentacenylene group; and

[0275] a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, and a pentacenylene group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro

group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, a C_1 - C_{60} alkoxy group, a C_3 - C_{10} cycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_6 - C_{60} aryloxy group, a C_6 - C_{60} arylthio group, a C_7 - C_{60} arylalkyl group, a C_1 - C_{60} heteroaryl group, a C_1 - C_{60} heteroaryloxy group, a C_1 - C_{60} heteroarylthio group, a C_2 - C_{60} heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

[0276] In Formula 201, xa and xb may each independently be an integer from 0 to 5, or 0, 1, or 2. For example, xa is 1 and xb is 0, but xa and xb are not limited thereto.

[0277] R_{101} to R_{108} , R_{111} to R_{119} , and R_{121} to R_{124} in Formulae 201 and 202 may each independently be selected from:

[0278] hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{10} alkyl group (for example, a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a hexyl group, and so on), or a C_1 - C_{10} alkoxy group (for example, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, and so on);

[0279] a C_1 - C_{10} alkyl group or a C_1 - C_{10} alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, and a phosphoric acid group or a salt thereof;

[0280] a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group; and

[0281] a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{10} alkyl group, and a C_1 - C_{10} alkoxy group, but embodiments of the present disclosure are not limited thereto.

[0282] R_{109} in Formula 201 may be selected from:


[0283] a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group; and

[0284] a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group, each substituted with at least

one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{20} alkyl group, a C_1 - C_{20} alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group.

[0285] According to an embodiment, the compound represented by Formula 201 may be represented by Formula 201A, but embodiments of the present disclosure are not limited thereto:


Formula 201A



[0286] R_{101} , R_{111} , R_{112} , and R_{109} in Formula 201A may be understood by referring to the description provided herein.


[0287] For example, the compound represented by Formula 201, and the compound represented by Formula 202 may include compounds HT1 to HT20 illustrated below, but are not limited thereto.

HT1




-continued

HT2




HT3




-continued

HT4




-continued


HT6



HT5




HT7



-continued


HT8




HT9

-continued


HT11





HT12



HT10




HT13




-continued


HT14




HT15



HT16




HT17




-continued


HT18



HT19



HT20




[0288] A thickness of the hole transport region may be in a range of about 100 Angstroms (Å) to about 10,000 Å, for example, about 100 Å to about 1,000 Å. When the hole transport region includes at least one of a hole injection layer and a hole transport layer, the thickness of the hole injection layer may be in a range of about 100 Å to about 10,000 Å, and for example, about 100 Å to about 1,000 Å, and the thickness of the hole transport layer may be in a range of about 50 Å to about 2,000 Å, and for example, about 100 Å to about 1,500 Å. While not wishing to be bound by theory, it is understood that when the thicknesses of the hole transport region, the hole injection layer, and the hole transport layer are within these ranges, satisfactory hole transporting characteristics may be obtained without a substantial increase in driving voltage.


[0289] The hole transport region may further include, in addition to these materials, a charge-generation material for the improvement of conductive properties. The charge-

generation material may be homogeneously or non-homogeneously dispersed in the hole transport region.

[0290] The charge-generation material may be, for example, a p-dopant. The p-dopant may be one selected from a quinone derivative, a metal oxide, and a compound including a cyano group, but embodiments of the present disclosure are not limited thereto. Non-limiting examples of the p-dopant are a quinone derivative, such as tetracyanoquinonodimethane (TCNQ) or 2,3,5,6-tetrafluoro-tetracyano-1,4-benzoquinonodimethane (F4-TCNQ); a metal oxide, such as a tungsten oxide or a molybdenum oxide; and a compound including a cyano group, such as Compound HT-D1 below, but are not limited thereto.



HT-D1



F4-TCNQ

[0291] The hole transport region may include a buffer layer.


[0292] Also, the buffer layer may compensate for an optical resonance distance according to a wavelength of light emitted from the emission layer, and thus, efficiency of a formed organic light-emitting device may be improved.

[0293] Then, an emission layer may be formed on the hole transport region by vacuum deposition, spin coating, casting, LB deposition, or the like. When the emission layer is formed by vacuum deposition or spin coating, the deposition or coating conditions may be similar to those applied in forming the hole injection layer although the deposition or coating conditions may vary according to a compound that is used to form the emission layer.


[0294] Meanwhile, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be selected from materials for the hole transport region described above and materials for a host to be explained later. However, the material for the electron blocking layer is not limited thereto. For example, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be mCP, which will be explained later.

[0295] The emission layer may include a host and a dopant, and the dopant may include the organometallic compound represented by Formula 1.


[0296] The host may include at least one selected from TPBi, TBADN, ADN (also referred to as "DNA"), CBP, CDBP, TCP, mCP, Compound H50, and Compound H51:




TPBi




TBADN




ADN



CBP




CDBP



[0297] In one or more embodiments, the host may further include a compound represented by Formula 301 below.

Formula 301



[0298] Ar_{111} and Ar_{112} in Formula 301 may each independently be selected from:

[0299] a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group; and

[0300] a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group.

[0301] Ar_{113} to Ar_{116} in Formula 301 may each independently be selected from:

[0302] a C_1 - C_{10} alkyl group, a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group; and

[0303] a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group.


[0304] g, h, i, and j in Formula 301 may each independently be an integer from 0 to 4, and may be, for example, 0, 1, or 2.

[0305] Ar_{113} to Ar_{116} in Formula 301 may each independently be selected from

[0306] a C_1 - C_{10} alkyl group, substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group;

[0307] a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl, a phenanthrenyl group, and a fluorenyl group;


[0308] a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{60} alkyl group, a C_2 - C_{60} alkenyl group, a C_2 - C_{60} alkynyl group, a C_1 - C_{60} alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group; and



[0309] but embodiments of the present disclosure are not limited thereto.

[0310] In one or more embodiments, the host may include a compound represented by Formula 302 below:

Formula 302




[0311] Ar_{122} to Ar_{125} in Formula 302 are the same as described in detail in connection with Ar_{113} in Formula 301.


[0312] Ar_{126} and Ar_{127} in Formula 302 may each independently be a C_1 - C_{10} alkyl group (for example, a methyl group, an ethyl group, or a propyl group).

[0313] k and l in Formula 302 may each independently be an integer from 0 to 4. For example, k and l may be 0, 1, or 2.


[0314] The compound represented by Formula 301 and the compound represented by Formula 302 may include Compounds H1 to H42 illustrated below, but are not limited thereto.




H1




H2



H3




H4




H5


-continued




H6




H7



H8




H9




H10

-continued


H11




H12




H13




H14



H15




H16




-continued


H17




H18




H19




H20




-continued




H21




H22



H23




H24




H25


-continued




H26




H27




H28



H29




H30




H31

-continued


H32




H33



H34




H35




-continued


H36



H37




H38




-continued


H39



H40




H41



-continued

H42



[0315] When the organic light-emitting device is a full-color organic light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and a blue emission layer. In one or more embodiments, due to a stacked structure including a red emission layer, a green emission layer, and/or a blue emission layer, the emission layer may emit white light.

[0316] When the emission layer includes a host and a dopant, an amount of the dopant may be in a range of about 0.01 parts by weight to about 15 parts by weight based on 100 parts by weight of the host, but embodiments of the present disclosure are not limited thereto.

[0317] A thickness of the emission layer may be in a range of about 100 Å to about 1,000 Å, for example, about 200 Å to about 600 Å. While not wishing to be bound by theory, it is understood that when the thickness of the emission layer is within this range, excellent light-emission characteristics may be obtained without a substantial increase in driving voltage.


[0318] Then, an electron transport region may be disposed on the emission layer.

[0319] The electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.


[0320] For example, the electron transport region may have a hole blocking layer/electron transport layer/electron injection layer structure or an electron transport layer/electron injection layer structure, but the structure of the electron transport region is not limited thereto. The electron transport layer may have a single-layered structure or a multi-layered structure including two or more different materials.

[0321] Conditions for forming the hole blocking layer, the electron transport layer, and the electron injection layer which constitute the electron transport region may be understood by referring to the conditions for forming the hole injection layer.


[0322] When the electron transport region includes a hole blocking layer, the hole blocking layer may include, for example, at least one of BCP, Bphen, and BAQ but embodiments of the present disclosure are not limited thereto.




BCP



Bphen



TAZ




NTAZ

[0323] A thickness of the hole blocking layer may be in a range of about 20 Å to about 1,000 Å, for example, about 30 Å to about 300 Å. While not wishing to be bound by theory, it is understood that when the thickness of the hole blocking layer is within these ranges, the hole blocking layer may have improved hole blocking ability without a substantial increase in driving voltage.




[0324] The electron transport layer may further include at least one selected from BCP, Bphen, Alq₃, BAlq, TAZ, and NTAZ.

[0325] In one or more embodiments, the electron transport layer may include at least one of ET1 and ET2, but are not limited thereto:

ET1



ET2


Alq₃

BAlq


[0326] A thickness of the electron transport layer may be in a range of about 100 to about 1,000 Å, for example, about 150 Å to about 500 Å. While not wishing to be bound by theory, it is understood that when the thickness of the electron transport layer is within the range described above, the electron transport layer may have satisfactory electron transport characteristics without a substantial increase in driving voltage.

[0327] Also, the electron transport layer may further include, in addition to the materials described above, a metal-containing material.

[0328] The metal-containing material may include a Li complex. The Li complex may include, for example, Compound ET-D1 (lithium quinolate, LiQ) or ET-D2.



ET-D1



ET-D2

[0329] The electron transport region may include an electron injection layer) that promotes flow of electrons from the second electrode 19 therein.

[0330] The electron injection layer may include at least one selected from LiF, NaCl, CsF, Li₂O, and BaO.

[0331] A thickness of the electron injection layer may be in a range of about 1 Å to about 100 Å, for example, about 3 Å to about 90 Å. While not wishing to be bound by theory, it is understood that when the thickness of the electron injection layer is within the range described above, the electron injection layer may have satisfactory electron injection characteristics without a substantial increase in driving voltage.

[0332] The second electrode 19 is disposed on the organic layer 15. The second electrode 19 may be a cathode. A material for forming the second electrode 19 may be selected from metal, an alloy, an electrically conductive compound, and a combination thereof, which have a relatively low work function. For example, lithium (Li), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag) may be used as a material for forming the second electrode 19. In one or more embodiments, to manufacture a top-emission type light-emitting device, a transmissive electrode formed using ITO or IZO may be used as the second electrode 19.

[0333] Hereinbefore, the organic light-emitting device has been described with reference to the FIGURE, but embodiments of the present disclosure are not limited thereto.

[0334] Another aspect of the present disclosure provides a diagnostic composition including at least one organometallic compound represented by Formula 1.

[0335] The organometallic compound represented by Formula 1 provides high luminescent efficiency. Accordingly, a diagnostic composition including the organometallic compound may have high diagnostic efficiency.

[0336] The diagnostic composition may be used in various applications including a diagnosis kit, a diagnosis reagent, a biosensor, and a biomarker.

[0337] The term “C₁-C₆₀ alkyl group” as used herein refers to a linear or branched saturated aliphatic hydrocarbon monovalent group having 1 to 60 carbon atoms, and non-limiting examples thereof include a methyl group, an ethyl group, a propyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, pentyl group, an iso-amyl group, and a hexyl group. The term “C₁-C₆₀ alkylene group” as used herein refers to a divalent group having the same structure as the C₁-C₆₀ alkyl group.

[0338] The term “C₁-C₆₀ alkoxy group” as used herein refers to a monovalent group represented by —OA₁₀₁ (wherein A₁₀₁ is the C₁-C₆₀ alkyl group), and non-limiting examples thereof include a methoxy group, an ethoxy group, and an iso-propyloxy (iso-propoxy) group.

[0339] The term “C₂-C₆₀ alkenyl group” as used herein refers to a hydrocarbon group formed by including at least one carbon-carbon double bond in the middle or at the terminus of the C₂-C₆₀ alkyl group, and examples thereof include an ethenyl group, a propenyl group, and a butenyl group. The term “C₂-C₆₀ alkenylene group” as used herein refers to a divalent group having the same structure as the C₂-C₆₀ alkenyl group.

[0340] The term “C₂-C₆₀ alkynyl group” as used herein refers to a hydrocarbon group formed by including at least one carbon-carbon triple bond in the middle or at the terminus of the C₂-C₆₀ alkyl group, and examples thereof include an ethynyl group, and a propynyl group. The term “C₂-C₆₀ alkynylene group” as used herein refers to a divalent group having the same structure as the C₂-C₆₀ alkynyl group.

[0341] The term “C₃-C₁₀ cycloalkyl group” as used herein refers to a monovalent saturated hydrocarbon monocyclic group having 3 to 10 carbon atoms, and non-limiting examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group. The term “C₃-C₁₀ cycloalkylene group” as used herein refers to a divalent group having the same structure as the C₃-C₁₀ cycloalkyl group.

[0342] The term “C₁-C₁₀ heterocycloalkyl group” as used herein refers to a monovalent saturated monocyclic group having at least one heteroatom selected from N, O, P, Si and S as a ring-forming atom and 1 to 10 carbon atoms, and non-limiting examples thereof include a tetrahydrofuranyl group, and a tetrahydrothiophenyl group. The term “C₁-C₁₀ heterocycloalkylene group” as used herein refers to a divalent group having the same structure as the C₁-C₁₀ heterocycloalkyl group.

[0343] The term “C₃-C₁₀ cycloalkenyl group” as used herein refers to a monovalent monocyclic group that has 3 to 10 carbon atoms and at least one carbon-carbon double bond in the ring thereof and that has no aromaticity, and

non-limiting examples thereof include a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. The term “C₃-C₁₀ cycloalkenylene group” as used herein refers to a divalent group having the same structure as the C₃-C₁₀ cycloalkenyl group.

[0344] The term “C₁-C₁₀ heterocycloalkenyl group” as used herein refers to a monovalent monocyclic group that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, 1 to 10 carbon atoms, and at least one carbon-carbon double bond in its ring. Examples of the C₁-C₁₀ heterocycloalkenyl group are a 2,3-dihydrofuran group, and a 2,3-dihydrothiophenyl group. The term “C₁-C₁₀ heterocycloalkenylene group” as used herein refers to a divalent group having the same structure as the C₁-C₁₀ heterocycloalkenyl group.

[0345] The term “C₆-C₆₀ aryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms, and the term “C₆-C₆₀ arylene group” as used herein refers to a divalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms. Non-limiting examples of the C₆-C₆₀ aryl group include a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, and a chrysenyl group. When the C₆-C₆₀ aryl group and the C₆-C₆₀ arylene group each include two or more rings, the rings may be fused to each other.

[0346] The term “C₁-C₆₀ heteroaryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, and 1 to 60 carbon atoms. The term “C₁-C₆₀ heteroarylene group” as used herein refers to a divalent group having a carbocyclic aromatic system that has at least one heteroatom selected from N, O, P, and S as a ring-forming atom, and 1 to 60 carbon atoms. Non-limiting examples of the C₁-C₆₀ heteroaryl group include a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group.

[0347] When the C₁-C₆₀ heteroaryl group and the C₁-C₆₀ heteroarylene group each include two or more rings, the rings may be fused to each other.

[0348] The term “C₆-C₆₀ aryloxy group” as used herein indicates —OA₁₀₂ (wherein A₁₀₂ is the C₆-C₆₀ aryl group), and a C₆-C₆₀ arylthio group as used herein indicates —SA₁₀₃ (wherein A₁₀₃ is the C₆-C₆₀ aryl group).

[0349] The term “monovalent non-aromatic condensed polycyclic group” as used herein refers to a monovalent group (for example, having 8 to 60 carbon atoms) having two or more rings condensed to each other, only carbon atoms as ring-forming atoms, and having no aromaticity in its entire molecular structure. Examples of the monovalent non-aromatic condensed polycyclic group include a fluorenyl group. The term “divalent non-aromatic condensed polycyclic group,” as used herein, refers to a divalent group having the same structure as the monovalent non-aromatic condensed polycyclic group.

[0350] The term “monovalent non-aromatic condensed heteropolycyclic group” as used herein refers to a monovalent group (for example, having 2 to 60 carbon atoms) having two or more rings condensed to each other, a heteroatom selected from N, O, P, Si, and S, other than carbon atoms, as a ring-forming atom, and having no aromaticity in its entire molecular structure. Non-limiting examples of the monovalent non-aromatic condensed het-

eropolycyclic group include a carbazolyl group. The term “divalent non-aromatic condensed heteropolycyclic group” as used herein refers to a divalent group having the same structure as the monovalent non-aromatic condensed heteropolycyclic group.

[0351] The term “C₅-C₃₀ carbocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, 5 to 30 carbon atoms only. The C₅-C₃₀ carbocyclic group may be a monocyclic group or a polycyclic group.

[0352] The term “C₁-C₃₀ heterocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, at least one heteroatom selected from N, O, Si, P, and S other than 1 to 30 carbon atoms. The C₁-C₃₀ heterocyclic group may be a monocyclic group or a polycyclic group.

[0353] At least one substituent of the substituted C₅-C₃₀ carbocyclic group, the substituted C₂-C₃₀ heterocyclic group, the substituted C₁-C₆₀ alkyl group, the substituted C₂-C₆₀ alkenyl group, the substituted C₂-C₆₀ alkynyl group, the substituted C₁-C₆₀ alkoxy group, the substituted C₃-C₁₀ cycloalkyl group, the substituted C₁-C₁₀ heterocycloalkyl group, the substituted C₃-C₁₀ cycloalkenyl group, the substituted C₁-C₁₀ heterocycloalkenyl group, the substituted C₆-C₆₀ aryl group, the substituted C₆-C₆₀ aryloxy group, the substituted C₆-C₆₀ arylthio group, the substituted C₇-C₆₀ arylalkyl group, the substituted C₁-C₆₀ heteroaryl group, the substituted C₁-C₆₀ heteroaryloxy group, the substituted C₁-C₆₀ heteroarylthio group, the substituted C₂-C₆₀ heteroarylalkyl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be selected from:

[0354] deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group; a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group,

[0355] a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₇-C₆₀ arylalkyl group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a C₂-C₆₀ heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁₁)(Q₁₂), —Si(Q₁₃)(Q₁₄)(Q₁₅), —B(Q₁₆)(Q₁₇), and —P(=O)(Q₁₈)(Q₁₉);

[0356] a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₇-C₆₀ arylalkyl group, a C₁-C₆₀ heteroaryl group, a

C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a C₂-C₆₀ heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

[0357] a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₇-C₆₀ arylalkyl group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a C₂-C₆₀ heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₇-C₆₀ arylalkyl group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a C₂-C₆₀ heteroarylalkyl group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₂₁)(Q₂₂), —Si(Q₂₃)(Q₂₄)(Q₂₅), —B(Q₂₆)(Q₂₇), and —P(=O)(Q₂₈)(Q₂₉); and

[0358] —N(Q₃₁)(Q₃₂), —Si(Q₃₃)(Q₃₄)(Q₃₅), —B(Q₃₆)(Q₃₇), and —P(=O)(Q₃₈)(Q₃₉), wherein

[0359] Q₁ to Q₉, Q₁₁ to Q₁₉, Q₂₁ to Q₂₉, and Q₃₁ to Q₃₉ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryl group substituted with at least one selected from a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₇-C₆₀ arylalkyl group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a C₂-C₆₀ heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.


[0360] Hereinafter, a compound and an organic light-emitting device according to embodiments are described in detail with reference to Synthesis Examples and Examples. However, the organic light-emitting device is not limited thereto. The wording “B was used instead of A” used in describing Synthesis Examples means that an amount of A used was identical to an amount of B used, in terms of molar equivalents.

EXAMPLES

Synthesis Example 1: Synthesis of Compound 1

Synthesis of Intermediate 1-2

[0361]






[0362] 4.03 grams (g) (20.1 millimoles, mmol) of 2-bromo-5-methyl-4-phenylpyridine (Intermediate 1-3) was mixed with 100 milliliters (mL) of toluene, 30 mL of ethanol, and 30 mL of water. To this mixture, 7.20 g (20.1 mmol) of (3-bromophenyl)boronic acid, 1.62 g (1.40 mmol) of palladium catalyst, and 5.28 g (50.1 mmol) of sodium carbonate were added. The resultant mixture was heated under reflux at a temperature of 120° C. for 18 hours. The product was concentrated under reduced pressure, mixed with 400 mL of dichloromethane, and filtered by using diatomite. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified by liquid chromatography to obtain 4.55 g (yield: 70%) of Intermediate 1-2.

[0363] LC-MS m/z=314 (M+H)⁺.

Synthesis of Intermediate 1-1

[0364]





6.58 g (20.3 mmol) of Intermediate 1-2 was mixed with 100 mL of toluene. To this mixture, 1.43 g (8.45 mmol) of [1,1'-biphenyl]-2-amine, 0.49 g (0.85 mmol) of $\text{Pd}(\text{dba})_2$, 1.1 g (2.54 mmol) of $\text{P}(\text{tBu})_3$, and 2.03 g (21.1 mmol) of sodium butoxide were added. The resultant mixture was heated under reflux at a temperature of 130° C. for 24 hours. The product was concentrated under reduced pressure and mixed with 200 mL of dichloromethane. The organic layer was dried by using magnesium sulfate, and the solvent was removed under reduced pressure. The residue was purified by liquid $(\text{M}+\text{H})^+$.

[0365] Synthesis of Compound 1



[0366] 2.10 g (3.2 mmol) of Intermediate 1-1 was mixed with 130 mL of benzonitrile at room temperature, and 1.51 g (3.20 mmol) of $\text{PtCl}_2(\text{NPh})_2$ was added thereto. The resultant mixture was heated under reflux at a temperature of 150° C. for 18 hours. After the completion of reaction was confirmed by LCMS, the reaction mixture was concentrated under reduced pressure and purified by liquid chromatography to obtain 0.6 g (yield: 28%) of Compound 1. Compound 1 was identified by Mass and HPLC.



[0367] HRMS (MALDI) calcd for $\text{C}_{48}\text{H}_{35}\text{N}_3\text{Pt}$: m/z 848.2479, Found: 848.2477.

Synthesis Example 2: Synthesis of Compound 2

Synthesis of Intermediate 2-2

[0368]






[0369] 5.50 g (17.0 mmol) of Intermediate 1-2 was mixed with 80 mL of toluene. To this mixture, 2.87 g (17.0 mmol) of [1,1'-biphenyl]-2-amine, 0.976 g (1.7 mmol) of $\text{Pd}(\text{dba})_2$, 2.06 g (0.30 mmol) of $\text{P}(\text{tBu})_3$, and 4.89 g (50.9 mmol) of sodium butoxide were added. The resultant mixture was heated under reflux at a temperature 130°C . for 18 hours. The product was concentrated under reduced pressure, mixed with 200 mL of dichloromethane, and filtered by using diatomite. The organic layer was dried by using magnesium sulfate, and the solvent was removed under reduced pressure.

[0370] Then, the residue was purified by liquid chromatography to obtain 4.3 g (yield: 61%) of Intermediate 2-2. LC-MS $m/z=413$ ($\text{M}+\text{H}$) $^+$.

Synthesis of Intermediate 2-1

[0371]




[0372] 3.5 g (78%) of Intermediate 2-1 was synthesized in the same manner as Intermediate 1-1 in Synthesis Example 1, except that 2.88 g (7.00 mmol) of Intermediate 2-2 and 2.83 g (9.1 mmol) of 2-(3-bromophenyl)-4-phenylpyridine (Intermediate 2-3) were each used instead of Intermediate 1-2 and [1,1'-biphenyl]-2-amine.


[0373] LC-MS $m/z=642$ ($\text{M}+\text{H}$) $^+$.

Synthesis of Compound 2

[0374]



-continued



Compound 2


[0375] 0.40 g (24%) of Compound 2 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 1.28 g (2.00 mmol) of Intermediate 2-1 was used instead of Intermediate 1-1. Compound 2 was identified by Mass and HPLC.

[0376] HRMS (MALDI) calcd for $C_{47}H_{33}N_3Pt$: m/z 834.2322, Found: 834.2322.


Synthesis Example 3: Synthesis of Compound 4

Synthesis of Intermediate 4-2


[0377]



1-3



-continued




4-2

[0378] 3.9 g (85%) of Intermediate 4-2 was synthesized in the same manner as Intermediate 1-2 in Synthesis Example 1, except that 3.42 g (13.3 mmol) of β -bromo-5-(tert-butyl)phenylboronic acid was used instead of (3-bromophenyl)boronic acid.


[0379] LC-MS m/z =380 ($M+H$)⁺.

Synthesis of Intermediate 4-1

[0380]



4-2



4-1


[0381] 2.94 g (79%) of Intermediate 4-1 was synthesized in the same manner as Intermediate 1-1 in Synthesis

Example 1, except that 0.825 g (4.88 mmol) of Intermediate 4-2 was used instead of Intermediate 1-2.

[0382] LC-MS $m/z=768$ ($M+H$)⁺.

Synthesis of Compound 4

[0383]




[0384] 0.43 g (12%) of Compound 4 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 2.94 g (3.83 mmol) of Intermediate 4-1 was used instead of Intermediate 1-1. Compound 4 was identified by Mass and HPLC.

[0385] HRMS (MALDI) calcd for $C_{56}H_{51}N_3Pt$: m/z 960.3731, Found: 960.3730.

Synthesis Example 4: Synthesis of Compound 7

Synthesis of Intermediate 7-1

[0386]





[0387] 2.80 g (58%) of Intermediate 7-1 was synthesized in the same manner as Intermediate 1-1 in Synthesis Example 1, except that 5.57 g (14.9 mmol) of Intermediate 7-2 was used instead of Intermediate 1-2.

[0388] LC-MS $m/z=756$ ($M+H$)⁺.

Synthesis of Compound 7

[0389]






[0390] 0.90 g (26%) of Compound 7 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 2.76 g (3.65 mmol) of Intermediate 7-1 was used instead of Intermediate 1-1. Compound 7 was identified by Mass and HPLC.

[0391] HRMS (MALDI) calcd for $C_{56}H_{39}N_3Pt$: m/z 948.2792, Found: 948.2790.

Synthesis Example 5: Synthesis of Compound 9

Synthesis of Intermediate 9-3


[0392]



[0393] 17.1 g (54.9 mmol) of Intermediate 9-4 and 550 mL of tetrahydrofuran (THF) were mixed, and the mixture was stirred at a temperature of -78°C . for 10 minutes. To this mixture, *n*-butyllithium (23.0 mL of a 2.5 M solution in hexanes, 57.6 mmol) was slowly added by drops for 30 minutes, and the resultant mixture was stirred at a temperature of -78°C . for 4 hours. Then, 12.3 mL (60.4 mmol) of 2-isopropoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane was added thereto, and after 15 minutes, the resultant mixture was warmed to room temperature and stirred for 5 hours. 200 mL of distilled water was added thereto, and the resultant mixture was stirred. Then, methylene chloride (200 mL $\times$ 3) was added thereto. The organic layer was dried by using MgSO_4 , and the solvent was evaporated. The residue was purified by liquid chromatography to obtain 9.0 g (yield: 46%) of Intermediate 9-3. MALDI-TOF $m/z=359$ ($M+H$) $^{+}$.

Synthesis of Intermediate 9-2

[0394]




[0395] 4.55 g (85%) of Intermediate 9-2 was synthesized in the same manner as Intermediate 1-2 in Synthesis Example 1, except that 5.83 g (16.2 mmol) of Intermediate 9-3 was used instead of (3-bromophenyl)boronic acid.

[0396] LC-MS $m/z=400$ ($M+H$) $^{+}$.

Synthesis of Intermediate 9-1

[0397]




[0398] 2.30 g (61%) of Intermediate 9-1 was synthesized in the same manner as Intermediate 1-1 in Synthesis Example 1, except that 4.52 g (11.3 mmol) of Intermediate 9-2 was used instead of Intermediate 1-2.


[0399] LC-MS $m/z=808$ ($M+H$)⁺.

Synthesis of Compound 9

[0400]



-continued





[0401] 0.30 g (11%) of Compound 9 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 2.30 g (2.87 mmol) of Intermediate 9-1 was used instead of Intermediate 1-1. Compound 9 was identified by Mass and HPLC.

[0402] HRMS (MALDI) calcd for $C_{60}H_{43}N_3Pt$: m/z 1000.3105, Found: 1000.3105.

Synthesis Example 6: Synthesis of Compound 17

Synthesis of Intermediate 17-2

[0403]





[0404] 4.11 g (59%) of Intermediate 17-2 was synthesized in the same manner as Intermediate 2-2 in Synthesis Example 2, except that 5.45 g (17.6 mmol) of Intermediate 17-3 was used instead of Intermediate 1-2.

[0405] LC-MS $m/z=399$ ($M+H$)⁺.

Synthesis of Intermediate 17-1

[0406]




17-1

[0407] 2.4 g (64%) of Intermediate 17-1 was synthesized in the same manner as Intermediate 2-1 in Synthesis Example 2, except that 2.07 g (5.20 mmol) of Intermediate 17-2 and 3.12 g (7.80 mmol) of Intermediate 17-4 were each used instead of Intermediate 2-2 and Intermediate 2-3.

[0408] LC-MS $m/z=718$ (M+H)⁺.

Synthesis of Compound 17

[0409]




[0410] 1.2 g (41%) of Compound 17 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 2.30 g (2.87 mmol) of Intermediate 17-1 was used instead of Intermediate 1-1. Compound 17 was identified by Mass and HPLC.

[0411] HRMS (MALDI) calcd for $C_{53}H_{37}N_3Pt$: m/z 910.2635, Found: 910.2633.

Synthesis Example 7: Synthesis of Compound 18

Synthesis of Intermediate 18-4

[0412]




[0413] 2.70 g (59%) of Intermediate 18-4 was synthesized in the same manner as Intermediate 2-2 in Synthesis Example 2, except that 4.77 g (14.3 mmol) of Intermediate 18-5 was used instead of Intermediate 1-2.


[0414] LC-MS $m/z=323$ (M+H)⁺.

Synthesis of Intermediate 18-2

[0415]



-continued




18-2

[0416] 2.50 g (50%) of Intermediate 18-2 was synthesized in the same manner as Intermediate 1-2 in Synthesis Example 1, except that Intermediate 18-3 and 4.33 g (12.1 mmol) of Intermediate 9-3 were each used instead of Intermediate 1-3 and (3-bromophenyl)boronic acid.


[0417] LC-MS $m/z=476$ (M+H)⁺.

Synthesis of Intermediate 18-1


[0418]




18-4



18-2



-continued




18-1

[0419] 2.47 g (62%) of Intermediate 18-1 was synthesized in the same manner as Intermediate 2-1 in Synthesis Example 2, except that 1.78 g (5.57 mmol) of Intermediate 18-4 and 2.65 g (5.57 mmol) of Intermediate 18-2 were each used instead of Intermediate 2-2 and Intermediate 2-3.

[0420] LC-MS $m/z=718$ (M+H)⁺.


Synthesis of Compound 18

[0421]



18-1






[0422] 1.1 g (50%) of Compound 18 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 1.73 g (2.41 mmol) of Intermediate 18-1 was used instead of Intermediate 1-1. Compound 18 was identified by Mass and HPLC.

[0423] HRMS (MALDI) calcd for $C_{53}H_{37}N_3Pt$: m/z 910.2635, Found: 910.2634.

Synthesis Example 8: Synthesis of Compound 21

Synthesis of Intermediate 21-2

[0424]




[0425] 4.55 g (70%) of Intermediate 21-2 was synthesized in the same manner as Intermediate 1-2 in Synthesis Example 1, except that 2-bromo-4-phenyl-5-(trimethylsilyl)pyridine and 5.21 g (17 mmol) of Intermediate 21-3 were each used instead of 2-bromo-5-methyl-4-phenylpyridine and Intermediate 1-2.

[0426] LC-MS $m/z=382$ ($M+H$)⁺.

Synthesis of Intermediate 21-1

[0427]





[0428] 2.45 g (61%) of Intermediate 21-1 was synthesized in the same manner as Intermediate 2-1 in Synthesis Example 2, except that 2.31 g (5.60 mmol) of Intermediate 2-2 and 2.14 g (5.60 mmol) of Intermediate 21-2 were each used instead of Intermediate 2-2 and Intermediate 2-3.

[0429] LC-MS $m/z=714$ ($M+H$)⁺.

Synthesis of Compound 21

[0430]





[0431] 1.10 g (37%) of Compound 21 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 2.31 g (3.31 mmol) of Intermediate 21-1 was used instead of Intermediate 1-1. Compound 21 was identified by Mass and HPLC.

[0432] HRMS (MALDI) calcd for $C_{48}H_{35}N_3Pt$: m/z 848.2479, Found: 848.2478.

Synthesis Example 9: Synthesis of Compound 26

Synthesis of Intermediate 26-1

[0433]





[0434] 2.04 g (61%) of Intermediate 26-1 was synthesized in the same manner as Intermediate 1-1 in Synthesis Example 1, except that 4.06 g (8.52 mmol) of Intermediate 17-2 was used instead of Intermediate 1-2.

[0435] LC-MS $m/z=960$ ($M+H$)⁺.

Synthesis of Compound 26

[0436]




[0437] 0.70 g (43%) of Compound 26 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 1.34 g (1.4 mmol) of Intermediate 26-1 was used instead of Intermediate 1-1. Compound 26 was identified by Mass and HPLC.

[0438] HRMS (MALDI) calcd for $C_{72}H_{51}N_3Pt$: m/z 1152.3731, Found: 1152.3732.

Synthesis Example 10: Synthesis of Compound 55

Synthesis of Intermediate 55-2

[0439]




[0440] 4.54 g (63%) of Intermediate 55-2 was synthesized in the same manner as Intermediate 2-2 in Synthesis Example 2, except that 4.62 g (12 mmol) of Intermediate 55-3 and 2.69 g (15.0 mmol) of naphthalen-1-amine were each used instead of Intermediate 1-2 and [1,1'-biphenyl]-2-amine.

[0441] LC-MS m/z =478 ($M+H$)⁺.

Synthesis of Intermediate 55-1

[0442]





[0443] 1.41 g (60%) of Intermediate 55-1 was synthesized in the same manner as Intermediate 2-1 in Synthesis Example 2, except that 1.53 g (3.40 mmol) of Intermediate 55-2 and 1.43 g (4.42 mmol) of Intermediate 1-2 were each used instead of Intermediate 2-2 and Intermediate 2-3.

[0444] LC-MS m/z =692 ($M+H$)⁺.

Synthesis of Compound 55

[0445]






[0446] 0.7 g (26%) of Compound 55 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 2.11 g (3.05 mmol) of Intermediate 55-1 was used instead of Intermediate 1-1. Compound 55 was identified by Mass and HPLC.

[0447] HRMS (MALDI) calcd for $C_{51}H_{35}N_3Pt$: m/z 884.2479, Found: 884.2478.

Synthesis Example 11: Synthesis of Compound 59

Synthesis of Intermediate 59-1

[0448]




[0449] 1.80 g (57%) of Intermediate 59-1 was synthesized in the same manner as Intermediate 1-1 in Synthesis Example 1, except that Intermediate 7-2 and 0.72 g (4.00 mmol) of naphthalen-1-amine were each used instead of Intermediate 1-2 and [1,1'-biphenyl]-2-amine.

[0450] LC-MS $m/z=782$ ($M+H$)⁺.

Synthesis of Compound 59

[0451]




[0452] 0.60 g (49%) of Compound 59 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 0.98 g (1.25 mmol) of Intermediate 59-1 was used instead of Intermediate 1-1. Compound 59 was identified by Mass and HPLC.

[0453] HRMS (MALDI) calcd for $C_{54}H_{37}N_3Pt$: m/z 922.2635, Found: 922.2634.


Synthesis Example 12: Synthesis of Compound 78

Synthesis of Intermediate 78-1

[0454]



17-2




78-1

[0455] 1.80 g (86%) of Intermediate 78-1 was synthesized in the same manner as Intermediate 1-1 in Synthesis Example 1, except that 2.35 g (4.96 mmol) of Intermediate 17-2 and 0.40 g (2.44 mmol) of naphthalen-1-amine were each used instead of Intermediate 1-2 and [1,1'-biphenyl]-2-amine.

[0456] LC-MS m/z =935 ($M+H$)⁺.


Synthesis of Compound 78

[0457]



78-1

-continued



Compound 78


[0458] 1.3 g (62%) of Compound 78 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 1.74 g (1.86 mmol) of Intermediate 78-1 was used instead of Intermediate 1-1. Compound 78 was identified by Mass and HPLC.

[0459] HRMS (MALDI) calcd for $C_{70}H_{49}N_3Pt$: m/z 1126.3574, Found: 1126.3572.


Synthesis Example 13: Synthesis of Compound 127

Synthesis of Intermediate 127-1

[0460]



1-2




127-1

[0461] 1.80 g (45%) of Intermediate 127-1 was synthesized in the same manner as Intermediate 1-1 in Synthesis Example 1, except that 1.47 g (5.18 mmol) of 4-(9H-carbazol-9-yl)-2,6-dimethylaniline was used instead of [1,1'-biphenyl]-2-amine.

[0462] LC-MS $m/z=773$ (M+H)⁺.

Synthesis of Compound 127

[0463]




[0464] 0.80 g (38%) of Compound 127 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 1.73 g (2.24 mmol) of Intermediate 127-1 was used instead of Intermediate 1-1. Compound 127 was identified by Mass and HPLC.

[0465] HRMS (MALDI) calcd for $C_{55}H_{42}N_3Pt$: m/z 965.3057, Found: 965.3053.

Synthesis Example 14: Synthesis of Compound 155

Synthesis of Intermediate 155-1

[0466]





[0467] 2.00 g (53%) of Intermediate 155-1 was synthesized in the same manner as Intermediate 1-1 in Synthesis Example 1, except that Intermediate 7-2 and 0.947 g (4.80 mmol) of 3,5-dimethyl-[1,1'-biphenyl]-2-amine were each used instead of Intermediate 1-2 and [1,1'-biphenyl]-2-amine.

[0468] LC-MS $m/z=785$ (M+H)⁺.

Synthesis of Compound 155

[0469]





[0470] 0.60 g (27%) of Compound 155 was synthesized in the same manner as Compound 1 in Synthesis Example 1, except that 1.83 g (2.30 mmol) of Intermediate 155-1 was used instead of Intermediate 1-1. Compound 155 was identified by Mass and HPLC.

[0471] HRMS (MALDI) calcd for $C_{58}H_{43}N_3Pt$: m/z 976.3105, Found: 976.3101.

Example 1

[0472] As an anode, a glass substrate, on which ITO/Ag/ITO were respectively deposited to have thicknesses of 70 Å/1,000 Å/70 Å, was cut to a size of 50 mm×50 mm×0.5 mm (mm=millimeters), sonicated with iso-propyl alcohol and pure water each for 5 minutes, and then cleaned by exposure to ultraviolet (UV) rays and ozone for 30 minutes. Then, the glass substrate was provided to a vacuum deposition apparatus.

[0473] 2-TNATA was deposited on the anode to form a hole injection layer having a thickness of 600 Å, and 4,4'-bis[N-(1-naphthyl)-N-phenylamino]biphenyl (NPB)

was deposited on the hole injection layer to form a hole transport layer having a thickness of 1,350 Å.

[0474] CBP (host) and Compound 1 (dopant) were co-deposited on the hole transport layer at a weight ratio of 98:2 to form an emission layer having a thickness of 400 Å, and BCP was deposited on the emission layer to form a hole blocking layer having a thickness of 50 Å. Then, Alq_3 was deposited on the hole blocking layer to form an electron transport layer having a thickness of 350 Å, LiF was deposited on the electron transport layer to form an electron injection layer having a thickness of 10 Å, and MgAg was deposited on the electron injection layer at a weight ratio of 90:10 to form a cathode having a thickness of 120 Å, thereby completing the manufacture of an organic light-emitting device.

Examples 2 to 14 and Comparative Examples 1 to 3

[0475] Organic light-emitting devices were manufactured in the same manner as in Example 1, except that Compounds shown in Table 2 were each used instead of Compound 1 as a dopant in forming an emission layer.

Evaluation Example 1: Evaluation of Characteristics of Organic Light-Emitting Devices

[0476] The driving voltage, quantum emission efficiency, lifespan characteristics, and maximum emission wavelength of organic light-emitting devices manufactured according to Examples 1 to 14 and Comparative Examples 1 to 3 were evaluated by using a current-voltage meter (Keithley 2400) and a luminance meter (Minolta Cs-1000A), and results thereof are shown in Table 2. The lifespan (T_{97}) indicates an amount of time that lapsed when luminance was 97% of initial luminance (100%). The driving voltage, quantum emission efficiency, and lifespan of Examples 1 to 14 and Comparative Examples 1 and 2 are relative values when the driving voltage, quantum emission efficiency, and lifespan of Comparative Example 3 were 100%.

TABLE 2

No.	Dopant compound No.	Driving voltage (% relative value)	Quantum emission		Maximum emission wavelength (nm)
			efficiency (EQE) (% relative value)	Lifespan (T_{97}) (% relative value)	
Example 1	1	83	126	556	615
Example 2	2	87	125	483	629
Example 3	4	69	125	250	620
Example 4	7	78	133	500	621
Example 5	9	78	136	556	623
Example 6	17	88	126	400	617
Example 7	18	70	123	294	618
Example 8	21	75	123	211	623
Example 9	26	72	144	444	625
Example 10	55	71	132	389	627
Example 11	59	70	140	633	619
Example 12	78	70	137	361	630
Example 13	127	74	126	339	612
Example 14	155	77	133	222	623
Comparative Example 1	A	84	122	170	607
Comparative Example 2	B	97	121	167	645

TABLE 2-continued

No.	Dopant compound No.	Driving voltage (%, relative value)	Quantum emission		
			efficiency (EQE) (%, relative value)	Lifespan (T ₉₇) (%, relative value)	Maximum emission wavelength (nm)
Comparative Example 3	C	100	100	100	604







TABLE 2-continued







No.	Dopant compound No.	Driving voltage (%, relative value)	Quantum emission		
			efficiency (EQE) (%, relative value)	Lifespan (T ₉₇) (%, relative value)	Maximum emission wavelength (nm)
					
	9				
					
	17				
					
	18				
					
	21				

TABLE 2-continued


No.	Dopant compound No.	Driving voltage (%, relative value)	Quantum emission		
			efficiency (EQE) (%, relative value)	Lifespan (T ₉₇) (%, relative value)	Maximum emission wavelength (nm)



26




55




59

TABLE 2-continued


No.	Dopant compound No.	Driving voltage (%, relative value)	Quantum emission		Maximum emission wavelength (nm)
			efficiency (EQE) (%, relative value)	Lifespan (T ₉₇) (%, relative value)	



78



127



155






TABLE 2-continued

No.	Dopant compound No.	Driving voltage (% relative value)	Quantum emission efficiency (EQE) (% relative value)	Lifespan (T ₉₇) (% relative value)	Maximum emission wavelength (nm)
					
					
	B				
	C				

[0477] Referring to Table 2, it has been determined that the organic light-emitting devices of Examples 1 to 14 have improved driving voltage, quantum emission efficiency, and lifespan characteristics, as compared with those of the organic light-emitting devices of Comparative Examples 1 to 3.


[0478] Since the organometallic compounds have excellent electrical characteristics and thermal stability, organic light-emitting devices including such organometallic compounds may have excellent driving voltage, efficiency, power, color purity, and lifespan characteristics. Also, due to excellent phosphorescent luminescence characteristics, such organometallic compounds may provide a diagnostic composition having high diagnostic efficiency.

[0479] It should be understood that embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each embodiment should typically be considered as available for other similar features or aspects in other embodiments.

[0480] While one or more embodiments have been described with reference to the figures, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present description as defined by the following claims.

What is claimed is:

1. An organometallic compound represented by Formula 1:



Formula 1

wherein, in Formula 1,

M is a first-row transition metal of the Periodic Table of Elements, a second-row transition metal of the Periodic Table of Elements, or a third-row transition metal of the Periodic Table of Elements,

X₁ is N,

X₂ to X₄ are each independently C or N,

two bonds selected from a bond between X₁ and M, a bond between X₂ and M, a bond between X₃ and M, and a bond between X₄ and M are each a coordinate bond, and the others thereof are each a covalent bond,

Y₁ to Y₆ are each independently C or N,

Y₇ and Y₈ are each independently C, N, O, Si, or S,

X₁ and Y₇, X₁ and Y₁, X₂ and Y₂, X₂ and Y₃, X₃ and Y₄, X₃ and Y₅, X₄ and Y₆, and X₄ and Y₈ are each linked via a chemical bond,

CY₁ is a C₁-C₃₀ heterocyclic group,

CY₂ to CY₄ are each independently a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group,

T₁ to T₃ are each independently selected from *—N[(L₅)_{b5}—(R₅)]—*, *—B(R₅)—*, *—P(R₅)—*, *—C(R₅)(R₆)—*, *—Si(R₅)(R₆)—*, *—Ge(R₅)(R₆)—*, *—S—*, *—Se—*, *—O—*, *—C(=O)—*, *—S(=O)—*, *—S(=O)₂—*, *—C(R₅)=, *—C(R₅)—*, *—C(R₅)=C(R₆)—*, *—C(S)—*, and *—C≡C—*,


L₅ is selected from a single bond, a substituted or unsubstituted C₅-C₃₀ carbocyclic group, and a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

b₅ is selected from 1 to 3, wherein, when b₅ is two or more, two or more groups L₅ are identical to or different from each other,

R₅ and R₆ are optionally linked via a first linking group to form a substituted or unsubstituted C₅-C₃₀ carbocyclic group or a substituted or unsubstituted C₁-C₃₀ heterocyclic group,

n₁ to n₃ are each independently 0, 1, 2, or 3, wherein, when n₁ is zero, *(T₁)_{n1}—* is a single bond, when n₂ is zero, *(T₂)_{n2}—* is a single bond, and when n₃ is zero, *(T₃)_{n3}—* is a single bond,

R₇₁ in Formula 1 is a group represented by Formula 71,



Formula 71

wherein, in Formula 71,

L_{71} is selected from:

a C_2 - C_{60} alkylene group; and

a C_2 - C_{60} alkylene group substituted with at least one selected from deuterium, a deuterated C_1 - C_{60} alkyl group, a C_3 - C_{10} cycloalkyl group, and a C_3 - C_{10} cycloalkenyl group,

b71 is 0, 1, or 2,


T_{71} is selected from:

a C_1 - C_{60} alkyl group; and

a C_1 - C_{60} alkyl group substituted with at least one selected from deuterium, a deuterated C_1 - C_{60} alkyl group, a C_3 - C_{10} cycloalkyl group, and a C_3 - C_{10} cycloalkenyl group,

c71 is an integer from 1 to 10,

R_{72} in Formula 1 is a group represented by Formula 72,



Formula 72

wherein, in Formula 72,

L_{72} is selected from:

a C_6 - C_{60} aryene group, a C_1 - C_{60} heteroarylene group, a divalent non-aromatic condensed polycyclic group, and a divalent non-aromatic condensed heteropolycyclic group; and

a C_6 - C_{60} aryene group, a C_1 - C_{60} heteroarylene group, a divalent non-aromatic condensed polycyclic group, and a divalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, a C_1 - C_{60} alkyl group, a deuterated C_1 - C_{60} alkyl group, a C_3 - C_{10} cycloalkyl group, a C_1 - C_{10} heterocycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_1 - C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group,

b72 is 0, 1, or 2,

T_{72} is selected from:

a C_6 - C_{60} aryl group, a C_1 - C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group; and

a C_6 - C_{60} aryl group, a C_1 - C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, a C_1 - C_{60} alkyl group, a deuterated C_1 - C_{60} alkyl group, a C_3 - C_{10} cycloalkyl group, a C_1 - C_{10} heterocycloalkyl group, a C_3 - C_{10} cycloalkenyl group, a C_1 - C_{10} heterocycloalkenyl group, a C_6 - C_{60} aryl group, a C_1 - C_{60} heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group,

c72 is an integer from 1 to 10,

wherein, in Formula 1,

a71 and a72 are each independently an integer from 1 to 5,

R_1 to R_6 are each independently selected from hydrogen, deuterium, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C_1 - C_{60} alkyl group, a substituted or

unsubstituted C_2 - C_{60} alkenyl group, a substituted or unsubstituted C_2 - C_{60} alkynyl group, a substituted or unsubstituted C_1 - C_{60} alkoxy group, a substituted or unsubstituted C_3 - C_{10} cycloalkyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkyl group, a substituted or unsubstituted C_3 - C_{10} cycloalkenyl group, a substituted or unsubstituted C_1 - C_{10} heterocycloalkenyl group, a substituted or unsubstituted C_6 - C_{60} aryl group, a substituted or unsubstituted C_6 - C_{60} aryloxy group, a substituted or unsubstituted C_6 - C_{60} arylthio group, a substituted or unsubstituted C_7 - C_{60} arylalkyl group, a substituted or unsubstituted C_1 - C_{60} heteroaryl group, a substituted or unsubstituted C_1 - C_{60} heteroaryloxy group, a substituted or unsubstituted C_1 - C_{60} heteroarylthio group, a substituted or unsubstituted C_2 - C_{60} heteroarylalkyl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q_1)(Q_2), —Si(Q_3)(Q_4)(Q_5), —B(Q_6)(Q_7), and —P(=O)(Q_8)(Q_9),

a1 to a4 are each independently 0, 1, 2, 3, 4, or 5,

Formula 1 does not include fluorine (—F),

two of groups R_1 in the number of a1 are optionally linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

two of groups R_2 in the number of a2 are optionally linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

two of groups R_3 in the number of a3 are optionally linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

two of groups R_4 in the number of a4 are optionally linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

two or more neighboring groups selected from R_1 to R_4 are optionally linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

one of R_5 and R_6 and one of R_1 to R_4 are optionally linked to form a substituted or unsubstituted C_5 - C_{30} carbocyclic group or a substituted or unsubstituted C_1 - C_{30} heterocyclic group,

at least one substituent of the substituted C_5 - C_{30} carbocyclic group, the substituted C_1 - C_{30} heterocyclic group, the substituted C_1 - C_{60} alkyl group, the substituted C_2 - C_{60} alkenyl group, the substituted C_2 - C_{60} alkynyl group, the substituted C_1 - C_{60} alkoxy group, the substituted C_3 - C_{10} cycloalkyl group, the substituted C_1 - C_{10} heterocycloalkyl group, the substituted C_3 - C_{10} cycloalkenyl group, the substituted C_1 - C_{10} heterocycloalkenyl group, the substituted C_6 - C_{60} aryl group, the substituted C_6 - C_{60} aryloxy group, the substituted C_6 - C_{60} arylthio group, the substituted C_7 - C_{60} arylalkyl group, the substituted C_1 - C_{60} heteroaryl group, the substituted C_1 - C_{60} heteroaryloxy group, the substituted C_1 - C_{60} heteroarylthio group, the substituted C_2 - C_{60} heteroarylalkyl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group is selected from:

deuterium, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group;

a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group, each substituted with at least one selected from deuterium, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₇-C₆₀ arylalkyl group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a C₂-C₆₀ heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁₁)(Q₁₂), —Si(Q₁₃)(Q₁₄)(Q₁₅), —B(Q₁₆)(Q₁₇), and —P(=O)(Q₁₈)(Q₁₉);

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₇-C₆₀ arylalkyl group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a C₂-C₆₀ heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₇-C₆₀ arylalkyl group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a C₂-C₆₀ heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₇-C₆₀ arylalkyl group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a C₂-C₆₀ heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₂₁)(Q₂₂), —Si(Q₂₃)(Q₂₄)(Q₂₅), —B(Q₂₆)(Q₂₇), and —P(=O)(Q₂₈)(Q₂₉); and

—N(Q₃₁)(Q₃₂), —Si(Q₃₃)(Q₃₄)(Q₃₅), —B(Q₃₆)(Q₃₇), and —P(=O)(Q₃₈)(Q₃₉), and

Q₁ to Q₉, Q₁₁ to Q₁₉, Q₂₁ to Q₂₉, and Q₃₁ to Q₃₉ are each independently selected from hydrogen, deuterium, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryl group substituted with at least one selected from a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₇-C₆₀ arylalkyl group, a C₁-C₆₀ heteroaryl group, a C₁-C₆₀ heteroaryloxy group, a C₁-C₆₀ heteroarylthio group, a C₂-C₆₀ heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

2. The organometallic compound of claim 1, wherein M is Pt or Pd.


3. The organometallic compound of claim 1, wherein

CY₁ is selected from a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, a tetrazole group, an oxazole group, an isoxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline group, and


CY₂ to CY₄ are each independently selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a pyrrole group, a thiophene group, a furan group, an indole group, a benzoborole group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a dibenzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-on group, a dibenzothiophene 5,5-dioxide group, an azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluorene-9-on group, an azadibenzothiophene 5,5-dioxide group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazo-

line group, a phenanthroline group, a pyrazole group, an imidazole group, a triazole group, a tetrazole group, an oxazole group, an isoxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, and a 5,6,7,8-tetrahydroquinoline group.


4. The organometallic compound of claim 1, wherein, in Formula 1,
a moiety represented by




and a moiety represented by



are identical to each other, and a moiety represented by



and a moiety represented by



are identical to each other.

5. The organometallic compound of claim 1, wherein T_1 to T_3 are each independently selected from $*-N[(L_5)_{b5}-(R_5)]-*$, $*-C(R_5)(R_6)-*$, $*-Si(R_5)(R_6)-*$, $*-S-*$, and $*-O-*$, and the sum of n_1 , n_2 , and n_3 is 1.

6. The organometallic compound of claim 1, wherein L_{71} is selected from:

a C_2 - C_{10} alkylene group; and
a C_2 - C_{10} alkylene group substituted with at least one selected from deuterium, a deuterated C_1 - C_{20} alkyl

group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbonanyl group, a norbonenyl group, a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group,

b_{71} is 0 or 1,

T_{71} is selected from:

a C_1 - C_{10} alkyl group; and

a C_1 - C_{10} alkyl group substituted with at least one selected from deuterium, a deuterated C_1 - C_{20} alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbonanyl group, a norbonenyl group, a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group, and

c_{71} is 1 or 2.

7. The organometallic compound of claim 1, wherein

L_{72} is selected from:

a phenylene group, a naphthylene group, a pyridinylene group, a pyrimidinylene group, a triazinylene group, a quinolinylene group, an isoquinolinylene group, a quinoxalinylene group, a quinazolinylene group, a fluorenylene group, a carbazolyene group, a dibenzofuranylene group, and a dibenzothiophenylene group; and
a phenylene group, a naphthylene group, a pyridinylene group, a pyrimidinylene group, a triazinylene group, a quinolinylene group, an isoquinolinylene group, a quinoxalinylene group, a quinazolinylene group, a fluorenylene group, a carbazolyene group, a dibenzofuranylene group, and a dibenzothiophenylene group, each substituted with at least one selected from deuterium, a C_1 - C_{20} alkyl group, a deuterated C_1 - C_{20} alkyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a fluorenyl group, a carbazoly group, a dibenzofuranyl group, and a dibenzothiophenyl group,

b_{72} is 0 or 1,

T_{72} is selected from:

a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a fluorenyl group, a carbazoly group, a dibenzofuranyl group, and a dibenzothiophenyl group; and

a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a fluorenyl group, a carbazoly group, a dibenzofuranyl group, and a dibenzothiophenyl group, each substituted with at least one selected from deuterium, a C_1 - C_{20} alkyl group, a deuterated C_1 - C_{20} alkyl group, a phenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, a triazinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a fluorenyl group, a carbazoly group, a dibenzofuranyl group, and a dibenzothiophenyl group, and

c_{72} is 1 or 2.

8. The organometallic compound of claim 1, wherein

R_1 to R_6 are each independently selected from:

hydrogen, deuterium, $-Cl$, $-Br$, $-I$, a hydroxyl group, a cyano group, a nitro group, an amino group, an

- amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, C_1 - C_{20} alkyl group, and a C_1 - C_{20} alkoxy group;
- a C_1 - C_{20} alkyl group and a C_1 - C_{20} alkoxy group, each substituted with at least one selected from deuterium, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C_1 - C_{10} alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;
- a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, and an imidazopyrimidinyl group;
- a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, —N(Q₃₁)(Q₃₂), and —Si(Q₃₃)(Q₃₄)(Q₃₅); and
- N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(=O)(Q₈)(Q₉), and
- Q₁ to Q₉ and Q₃₁ to Q₃₅ are each independently selected from:
- CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃, —CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCH₃, —CHDCD₂H, —CHDCDH₂, —CHDCD₃, —CD₂CD₃, —CD₂CD₂H, and —CD₂CDH₂;
- an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and
- an n-propyl group, an iso-propyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C_1 - C_{10} alkyl group, and a phenyl group.
9. The organometallic compound of claim 1, wherein
- R₁ to R₆ are each independently selected from hydrogen, deuterium, a cyano group, a nitro group, —CH₃, —CD₃, —CD₂H, —CDH₂, —OCH₃, groups repre-

sented by Formulae 9-1 to 9-19, groups represented by Formulae 10-1 to 10-168, $-\text{N}(\text{Q}_1)(\text{Q}_2)$, and $-\text{Si}(\text{Q}_3)(\text{Q}_4)(\text{Q}_5)$,


R_{71} is selected from $-\text{CH}_3$, $-\text{CD}_3$, $-\text{CD}_2\text{H}$, $-\text{CDH}_2$, groups represented by Formulae 9-1 to 9-19, and groups represented by Formulae 10-5 to 10-8, 10-11, and 10-12, and

R_{72} is selected from groups represented by Formulae 10-13 to 10-152 and 10-159 to 10-168:

-continued



Formula 9-1




Formula 9-2




Formula 9-3




Formula 9-4




Formula 9-5




Formula 9-6




Formula 9-7




Formula 9-8




Formula 9-9




Formula 9-10




Formula 9-11




Formula 9-12




Formula 9-13




Formula 9-14




Formula 9-15




Formula 9-16




Formula 9-17




Formula 9-18




Formula 9-19




Formula 10-1




Formula 10-2




Formula 10-3




Formula 10-4



Formula 10-5













Formula 10-6



Formula 10-7

-continued



Formula 10-8

Formula 10-9

Formula 10-10

Formula 10-11

Formula 10-12

Formula 10-13











Formula 10-14

Formula 10-15

Formula 10-16

Formula 10-17

-continued



Formula 10-18

Formula 10-19

Formula 10-20

Formula 10-21

Formula 10-22

Formula 10-23











Formula 10-24

Formula 10-25

Formula 10-26

Formula 10-27

-continued



Formula 10-28

Formula 10-29

Formula 10-30

Formula 10-31

Formula 10-32

Formula 10-33











Formula 10-34

Formula 10-35

Formula 10-36

Formula 10-37

-continued



Formula 10-38

Formula 10-39

Formula 10-40

Formula 10-41

Formula 10-42

Formula 10-43









Formula 10-44

Formula 10-45

Formula 10-46

Formula 10-47

-continued



Formula 10-48

Formula 10-49

Formula 10-50

Formula 10-51









Formula 10-52

Formula 10-53

Formula 10-54

Formula 10-55

-continued



Formula 10-56

Formula 10-57

Formula 10-58

Formula 10-59










Formula 10-60

Formula 10-61

Formula 10-62

Formula 10-63

-continued



Formula 10-64

Formula 10-65

Formula 10-66

Formula 10-67

Formula 10-68







Formula 10-69

Formula 10-70

Formula 10-71

Formula 10-72

-continued



Formula 10-73

Formula 10-74









Formula 10-75

Formula 10-76

Formula 10-77

Formula 10-78

-continued



Formula 10-79

Formula 10-80

Formula 10-81

Formula 10-82












Formula 10-83

Formula 10-84

Formula 10-85

Formula 10-86

-continued



Formula 10-87

Formula 10-88

Formula 10-89

Formula 10-90

Formula 10-91

Formula 10-92

Formula 10-93











Formula 10-94

Formula 10-95

Formula 10-96

Formula 10-97

-continued



Formula 10-98

Formula 10-99

Formula 10-100

Formula 10-101

Formula 10-102

Formula 10-103








Formula 10-104

Formula 10-105

Formula 10-106

Formula 10-107

-continued



Formula 10-108

Formula 10-109

Formula 10-110








Formula 10-111

Formula 10-112

Formula 10-113

Formula 10-114

-continued



Formula 10-115

Formula 10-116

Formula 10-117








Formula 10-118

Formula 10-119

Formula 10-120

Formula 10-121

-continued



Formula 10-122

Formula 10-123

Formula 10-124








Formula 10-125

Formula 10-126

Formula 10-127

Formula 10-128

-continued



Formula 10-129

Formula 10-130

Formula 10-131








Formula 10-132

Formula 10-133

Formula 10-134

Formula 10-135

-continued



Formula 10-136

Formula 10-137

Formula 10-138











Formula 10-139

Formula 10-140

Formula 10-141

Formula 10-142

-continued



Formula 10-143

Formula 10-144

Formula 10-145

Formula 10-146

Formula 10-147

Formula 10-148











Formula 10-149

Formula 10-150

Formula 10-151

Formula 10-152

-continued



Formula 10-153

Formula 10-154

Formula 10-155

Formula 10-156

Formula 10-157

Formula 10-158


Formula 10-159

Formula 10-160


Formula 10-161

Formula 10-162


-continued




Formula 10-163




Formula 10-164




Formula 10-165



Formula 10-166




Formula 10-167




Formula 10-168


10. The organometallic compound of claim 1, wherein a moiety represented by




in Formula 1 is selected from groups represented by Formulae CY1-1 to CY1-6:




Formula CY1-1




Formula CY1-2



Formula CY1-3




Formula CY1-4



Formula CY1-5

wherein, in Formulae 9-1 to 9-19 and 10-1 to 10-168, * indicates a binding site to a neighboring atom, "Ph" indicates a phenyl group, "Cz" indicates a carbazolyl group, and "TMS" indicates a trimethylsilyl group.

-continued




Formula CY1-6

wherein, in Formulae CY1-1 to CY1-6,
 X_1 , R_{71} , R_{72} , and R_1 are each independently the same as
 described in claim 1,


c_2 is an integer from 0 to 2, and

* and *' each indicate a binding site to a neighboring
 atom.


11. The organometallic compound of claim 1, wherein,
 a moiety represented by




Formula 1 is selected from groups represented by Formulae
 CY2-1 to CY2-25:




Formula CY2-1



Formula CY2-2




Formula CY2-3




Formula CY2-4


-continued




Formula CY2-5




Formula CY2-6




Formula CY2-7



Formula CY2-8










Formula CY2-9




Formula CY2-10


-continued




Formula CY2-11




Formula CY2-12




Formula CY2-13




Formula CY2-14




Formula CY2-15



Formula CY2-16



Formula CY2-17



-continued

Formula CY2-18

Formula CY2-19

Formula CY2-20

Formula CY2-21


Formula CY2-22

Formula CY2-23

Formula CY2-24

-continued

Formula CY2-25



wherein, in Formulae CY2-1 to CY2-25,

X_2 and R_2 are each independently the same as described in claim 1,

X_{21} is O, S, N(R_{21}), or C(R_{21})(R_{22}),

R_{21} to R_{28} are each independently the same as described in connection with R_2 in claim 1,

c_5 is an integer from 0 to 5,


c_4 is an integer from 0 to 4,

c_3 is an integer from 0 to 3,


c_2 is an integer from 0 to 2, and

*, $*$ 1, and $*$ '' each indicate a binding site to a neighboring atom.


12. The organometallic compound of claim 1, wherein a moiety represented by




in Formula 1 is selected from groups represented by Formulae CY3-1 to CY3-25:



Formula CY3-1




Formula CY3-2




Formula CY3-3

-continued


Formula CY3-4




Formula CY3-5




Formula CY3-6




Formula CY3-7




Formula CY3-8




Formula CY3-9




-continued




Formula CY3-10




Formula CY3-11




Formula CY3-12



Formula CY3-13




Formula CY3-14




화학식 Formula CY3-15


-continued




Formula CY3-16




Formula CY3-17




Formula CY3-18




Formula CY3-19



Formula CY3-20




Formula CY3-21




Formula CY3-22


-continued



Formula CY3-23



Formula CY3-24



Formula CY3-25

wherein, in Formulae CY3-1 to CY3-25,
 X_3 and R_3 are each independently the same as described
 in claim 1,

X_{31} is O, S, $N(R_{31})$, or $C(R_{31})(R_{32})$,

R_{31} to R_{38} are each independently the same as described
 in connection with R_3 in claim 1,

c_5 is an integer from 0 to 5,


c_4 is an integer from 0 to 4,

c_3 is an integer from 0 to 3,


c_2 is an integer from 0 to 2, and

$*$, $*'$, and $*''$ each indicate a binding site to a neighboring
 atom.

13. The organometallic compound of claim 1, wherein
 a moiety represented by




in Formula 1 is selected from groups represented by For-
 mulae CY4-1 to CY4-35:




Formula CY4-1


-continued




Formula CY4-2




Formula CY4-3




Formula CY4-4




Formula CY4-5



Formula CY4-6









Formula CY4-7



Formula CY4-8

-continued



Formula CY4-9

Formula CY4-10







Formula CY4-11

Formula CY4-12

Formula CY4-13

Formula CY4-14

-continued



Formula CY4-15

Formula CY4-16







Formula CY4-17

Formula CY4-18

Formula CY4-19

Formula CY4-20

-continued



Formula CY4-21

Formula CY4-22







Formula CY4-23

Formula CY4-24

Formula CY4-25

Formula CY4-26

-continued



Formula CY4-27

Formula CY4-28


Formula CY4-29

Formula CY4-30

Formula CY4-31

Formula CY4-32


-continued



Formula CY4-33

in Formula 1 is selected from groups represented by Formulae CY1(1) and CY1(2),


a moiety represented by




Formula CY4-34

in Formula 1 is selected from groups represented by Formulae CY2(1) to CY2(4),

a moiety represented by





Formula CY4-35



in Formula 1 is selected from groups represented by Formulae CY3(1) to CY3(4), and

a moiety represented by



wherein, in Formulae CY4-1 to CY4-35,
X₄ and R₄ are each independently the same as described in claim 1,

X₄₁ is O, S, N(R₄₁), or C(R₄₁)(R₄₂),

R_{71a} is the same as described in connection with R₇₁ in claim 1,

R_{72a} is the same as described in connection with R₇₂ in claim 1,

R₄₁ to R₄₈ are each independently the same as described in connection with R₄ in claim 1,

c₆ is an integer from 0 to 6,

c₅ is an integer from 0 to 5,


c₄ is an integer from 0 to 4,

c₃ is an integer from 0 to 3,

c₂ is an integer from 0 to 2, and


* and *' each indicate a binding site to a neighboring atom.

14. The organometallic compound of claim 1, wherein a moiety represented by




in Formula 1 is selected from groups represented by Formulae CY4(1) to CY4(19):









Formula CY1(1)




Formula CY1(2)




-continued




Formula CY2(1)




Formula CY2(2)




Formula CY2(3)




Formula CY2(4)




Formula CY3(1)




Formula CY3(2)



Formula CY3(3)



Formula CY3(4)



-continued

Formula CY4(1)

Formula CY4(2)

Formula CY4(3)

Formula CY4(4)


Formula CY4(5)

Formula CY4(6)


Formula CY4(7)

Formula CY4(8)


-continued




Formula CY4(9)




Formula CY4(10)




Formula CY4(11)




Formula CY4(12)



Formula CY4(13)




Formula CY4(14)




Formula CY4(15)


-continued




Formula CY4(16)



Formula CY4(17)



Formula CY4(18)



Formula CY4(19)

wherein, in Formulae CY1(1), CY1(2), CY2(1) to CY2(4), CY3(1) to CY3(4), and CY4(1) to CY4(19),

X_1 , R_1 , R_{71} , R_{72} , X_2 , R_2 , X_3 , R_3 , X_4 , and R_4 are each independently the same as described in claim 1,

X_{41} is O, S, N(R_{41}), or C(R_{41})(R_{42}),

R_{4a} , R_{4b} , R_{41} , and R_{42} are each independently the same as described in connection with R_4 in claim 1,


R_{71a} is the same as described in connection with R_{71} in claim 1,

R_{72a} is the same as described in connection with R_{72} in claim 1, and

*, *, and * each indicate a binding site to a neighboring atom.

15. The organometallic compound of claim 1, wherein being represented by Formula 1(1):

Formula 1(1)



wherein, in Formula 1(1),

M, X₁ to X₄, Y₁ to Y₈, CY₁ to CY₄, T₂, T₃, b₂, b₃, R₇₁, R₇₂, a₇₁, a₇₂, R₁ to R₄, and a₁ to a₄ are each independently the same as described in claim 1,

CY₅ and CY₆ are each independently be a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group,

R₅₁ and R₆₁ are each independently the same as described in connection with R₁ in claim 1,

a₅₁ and a₆₁ are each independently be 0, 1, 2, or 3,

T₄ is C, Si, or Ge,

T₅ is selected from a single bond, *—N[(L₇)_{b7}—(R₇)]—*, *—C(R₇)(R₈)—*, *—Si(R₇)(R₈)—*, *—Ge(R₇)(R₈)—*, *—S—*, *—Se—*, *—O—*, *—C(=O)—*, *—S(=O)—*, *—S(=O)₂—*, *—C(R₇)=C(R₈)—*, *—C(=S)—*, and *—C≡C—*,

L₇ and b₇ are each independently the same as described in connection with L₅ and b₅ in claim 1,


R₇ and R₈ are each independently the same as described in connection with R₅, and

* and *' each indicate a binding site to a neighboring atom.


16. The organometallic compound of claim 1, wherein the organometallic compound is selected from Compounds 1 to 201:

-continued


2




3




4



1




-continued




5


-continued




8




6



9




7




10

-continued


11



12




13




-continued


14



15




16




-continued


17



18




19




-continued


20



21




22




-continued

23




-continued


26




24




27



25




28




-continued

29




-continued


32



30





33




34

31




-continued




35


-continued




38




36



39




37




40

-continued




41


-continued




44




42



45




43




46


-continued




-continued




48




51




49



52




-continued




53


-continued




56




54



57




55



58


-continued

59




-continued


62




60




63




61



64




-continued




65


-continued




68




66



69




67




70

-continued




71


-continued




74




72



75




73



76


-continued

77




-continued


80




78




81




79



82




-continued




83


-continued




86




84



87




85



88


-continued

89




-continued


92




90




93



91




94




-continued

95




-continued


98




96




99



97




100




-continued

101





-continued

104




105


102



103




106




-continued

107





-continued

109




110

108





111




-continued

112




114




-continued


115



116




117




-continued


118



119




120




-continued


121



122




-continued




123

-continued





126





124




125



127




-continued




132



-continued



135




134



136


-continued

137




-continued


139



138




140




161

-continued




141

-continued




143


142



144




-continued




145

-continued




147

146




148




-continued

149




-continued

152




150



153



151




154




-continued


155



156




157




-continued


158



159




-continued




160


-continued




163



161




162



164


-continued

165




-continued


167




168




166



169




-continued




170


-continued




173




171



174




172



175


168

-continued




176

-continued




178

177




179




-continued


180



181




182




-continued

183




184




170

-continued




185

-continued




187

186




188




-continued


189



190




191




-continued


192



193




194




-continued

195




-continued

197




198



196



199



-continued



17. An organic light-emitting device comprising:

a first electrode;

a second electrode; and

an organic layer that is disposed between the first electrode and the second electrode,

wherein the organic layer comprises an emission layer and at least one of the organometallic compound of claim 1.

18. The organic light-emitting device of claim 17, wherein the first electrode is an anode,

the second electrode is a cathode,

the organic layer further comprises a hole transport region disposed between the first electrode and the emission layer and an electron transport region disposed between the emission layer and the second electrode,

wherein the hole transport region comprises a hole injection layer, a hole transport layer, an electron blocking layer, or any combination thereof, and

wherein the electron transport region comprises a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

19. The organic light-emitting device of claim 17, wherein the emission layer comprises the organometallic compound.

20. The organic light-emitting device of claim 19, wherein the emission layer further comprises a host, and

an amount of the host in the emission layer is larger than an amount of the organometallic compound in the emission layer.

21. A diagnostic composition comprising at least one of the organometallic compound of claim 1.

* * * * *

专利名称(译)	有机金属化合物，包括有机金属化合物的有机发光装置和包含有机金属化合物的诊断组合物		
公开(公告)号	US20180261781A1	公开(公告)日	2018-09-13
申请号	US15/913153	申请日	2018-03-06
[标]申请(专利权)人(译)	三星电子株式会社		
申请(专利权)人(译)	SAMSUNG ELECTRONICS CO. , LTD.		
当前申请(专利权)人(译)	SAMSUNG ELECTRONICS CO. , LTD.		
[标]发明人	LEE KUM HEE LEE BANGLIN KIM SUNGJUN CHO HWAYOUNG CHOI JONGWON CHOI WHAIL KWAK YOONHYUN KWON OHYUN		
发明人	LEE, KUM HEE LEE, BANGLIN KIM, SUNGJUN CHO, HWAYOUNG CHOI, JONGWON CHOI, WHAIL KWAK, YOONHYUN KWON, OHYUN		
IPC分类号	H01L51/00 C07F15/00 C09K11/06		
CPC分类号	H01L51/0087 C07F15/0086 C09K11/06 H01L51/5024 H01L51/5088 H01L51/5056 H01L51/5096 H01L51/5072 H01L51/5092 H01L51/5016 H01L51/5004 H01L2251/552 C09K2211/185 C09K2211/1029		
优先权	1020170029058 2017-03-07 KR 1020180026193 2018-03-06 KR		
外部链接	Espacenet USPTO		

摘要(译)

由式1表示的有机金属化合物：其中，在公式1中，组和变量与规范中描述的相同。

